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Abstract 
Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder and is 
increasing in incidence and prevalence in ageing populations. It is estimated that 1.5-2% of 
the developed world suffers from AF. The risk of stroke and thromboembolism (TE) is 
increased 4-5 fold by non-valvular atrial fibrillation (NVAF) and nearly 15% of all strokes are 
caused by AF. Judicious use of antithrombotic therapy significantly reduces the risk of stroke 
for most patients who have AF. Conversely, underuse of antithrombotic therapy is associated 
with an increase in the rates of death and ischaemic events (stroke, transient ischaemic attack 
[TIA], or myocardial infarction [MI]). Despite the proven benefits of anticoagulant therapy 
among high-risk patients with AF, there have been frequent reports of discordance between 
guideline recommendations and anticoagulant prescribing patterns leading to problem of 
underutilisation in patients with AF in real-world practices.  
During the time period of this study there were limited data available on the 
characteristics, clinical management and outcomes of patients with AF from an Australian 
perspective. The available literature suggested that there was underutilisation of anticoagulant 
therapy, although this data came from relatively small observational trials in selected patient 
groups. The Commonwealth Review of Anticoagulation Therapies in AF in Australia 
identified that stroke prevention in individuals with AF required improvement, and 
highlighted a range of issues to be addressed related to the assessment of patients for stroke 
and bleeding risk, appropriate choice of antithrombotic agent(s) in patients with multiple 
comorbidities, and the monitoring of patients. The review stressed the need for local data on 
which to base recommendations regarding the treatment of AF. Meanwhile, little was known 
about the clinical outcomes and safety of direct oral anticoagulants (DOACs) outside the trial 
setting. In 2011, dabigatran’s sponsor launched a patient familiarisation program in which 
xxiv 
over 28,000 Australians were enrolled. Thus, we established that there was a critical need for 
local data regarding the safety of antithrombotic medications, including the DOACs, in the 
treatment of AF. We designed this study, the Tasmanian AF (TAF) Study, as a starting point 
to providing comprehensive data describing the outcomes of stroke prevention strategies in 
Tasmanian patients with AF. The TAF study is an ongoing retrospective study that enrols 
patients from 3 different hospitals in Tasmania, Australia; the Royal Hobart Hospital (RHH), 
Launceston General Hospital (LGH) and North West Regional Hospital (NWRH). The 
rationale behind this project was to derive local data on usage pattern of antithrombotic 
therapy, clinical outcomes and their safety profile in Australian sub-population - initially 
prior to the Pharmaceutical Benefits Scheme (PBS) listing of DOACs, and then to use the 
established database to monitor the impact of the introduction of the DOACs into clinical 
practice. 
Our main objectives in the work reported here were to retrospectively i) review the 
patient characteristics and antithrombotic treatment patterns among patients with AF in 
Tasmanian hospitals, ii) compare the anticoagulant utilisation to earlier data in the same 
population and identify predictors of anticoagulant prescribing among patients with NVAF, 
iii) evaluate the rates of, and factors associated with, hospital readmissions due to bleeding or
TE complications among patients newly diagnosed with AF, and iv) compare the patient 
characteristics, antithrombotic prescribing patterns, and rates of bleeding or TE outcomes 
between older and younger patients diagnosed with AF. 
To study the patient characteristics and antithrombotic prescribing patterns we 
reviewed and followed patients with AF admitted to Tasmania’s 3 major hospitals between 
January 2011 and June 2012. In identifying the predictors of anticoagulant prescribing among 
 
 
xxv 
 
patients with NVAF and to compare the anticoagulant utilisation pattern to earlier data in the 
same population, we reviewed patients only with NVAF from the above population. To 
examine the rates of, and factors associated, with hospital readmission due to bleeding and 
TE, we recruited patients newly diagnosed with AF and admitted to the RHH between 1
st
 
January 2011 and 30
th
 June 2012 and followed them for the first 3 months, and then at least 
18 months, from the time of hospital discharge after their index admission. During short-term 
follow-up, patients were followed for 3 months from time of hospital discharge after their 
index admission with newly diagnosed AF or until the occurrence of a primary outcome or 
death, whichever came first. Similarly, for longer-term follow-up, patients were followed for 
at least 18 months from time of hospital discharge after their index admission with newly 
diagnosed AF, or until the occurrence of a primary outcome, death or December 31, 2013, 
whichever occurred first. Finally, to compare the patient characteristics, antithrombotic 
prescribing patterns, and rates of bleeding or TE outcomes between older and younger 
patients diagnosed with AF, we divided patients into two age groups - a younger group aged 
<75 and an older group aged 75 or above. Included patients were then followed from their 
index admission for at least 18 months from time of hospital discharge after their index 
admission or until the occurrence of a primary outcome, death or December 31, 2013, 
whichever occurred first. Our primary outcomes were readmissions due to: 1) major bleeding, 
including haemorrhagic stroke requiring hospitalisation, and 2) TE (ischaemic stroke and 
systemic embolism, MI and TIA). 
   
Our patient population demonstrated high rates of comorbid conditions, especially 
cardiovascular disease. Nevertheless, their characteristics proved to be largely similar to some 
of the populations studied in international registries. Our study also compares well to the 
patient cohorts studied in clinical trials comparing DOACs to warfarin, in terms of mean age 
xxvi 
and stroke risk. As seen in other real-world studies we also observed discordance between AF 
guideline recommendations and anticoagulant prescribing patterns despite the high risk of 
stroke observed. We also observed the relatively high rate of prescribing of combination 
anticoagulant/antiplatelet therapy in patients newly initiated on therapy and among those with 
existing AF from admission to discharge. In another study designed to compare the 
anticoagulant utilisation pattern to 15 year earlier data in the same population, and identify 
the predictors of anticoagulant prescribing among patients with NVAF, we observed that 
while there has been improvement over the past 15 years, suboptimal use of anticoagulant 
therapy among high risk patients with NVAF remains common. Younger age (odds ratio 
[OR] 0.99, 95% CI 0.97-1.0; P=0.04), CHADS2=1, relative to 0 (OR 1.68, 95% CI 1.07-2.63; 
P=0.02), CHF (OR 1.56, 95% CI 1.12-2.15; P=0.008) and embolic disease history (OR 1.77, 
95% CI 1.09-2.86; P=0.02) were significant predictors of anticoagulant prescribing. Despite 
guideline recommendations, we did not observe CHADS2 ≥2 as a significant predictor of 
anticoagulant prescribing in our population.  
In our study to evaluate the rates of, and factors associated with, hospital 
readmissions due to bleeding or TE complications among patients newly diagnosed with AF, 
the rates per 100 person-years (PY) of bleeding and TE-related readmissions within 3 months 
were 4.8 (95% CI 2.2-7.5) and 8.1 (95% CI 4.8-11.4), respectively. The rates per 100 PY of 
bleeding and TE-related readmissions during a mean of 2.1 years’ follow-up were 1.5 (95% 
CI 0.02-3.0) and 3.7 (95% CI 1.4-6.0), respectively. Patients with peripheral vascular disease 
(PVD) (OR 8.1, 95% CI 1.3-52.1) and renal impairment (OR 15.1, 95% CI 2.3-101.2) were 
more likely to be readmitted for bleeding, while those with a history of MI (OR 6.3, 95% CI 
2.2-18.1) were more likely to be readmitted for TE during longer-term follow-up. We thus 
xxvii 
observed higher rates of bleeding or TE-related readmissions in the initial 3 months following 
AF diagnosis and initiation of treatment.  
Finally in our study to compare the patient characteristics, antithrombotic prescribing 
patterns, and rates of bleeding or TE outcomes between older and younger patients diagnosed 
with AF, we observed that among high-risk patients aged ≥75 years, only 51.8% received 
anticoagulant treatment (vs. 64.6% in the younger group; P=0.02). After a mean follow-up of 
2.2 years, elderly patients were observed to be at higher risk of major bleeding (hazard ratio 
(HR) 3.2, 95% CI) 1.4-7.5, P=0.004) but the incidence of TE did not differ significantly (HR 
1.5, 95% CI 0.9-2.7, P=0.15) between the groups. Elderly patients prescribed anticoagulant 
therapy were at significantly higher risk of major bleeding (HR 3.0, 95% CI 1.1-8.3, P=0.02) 
but at similar risk of TE (HR 0.9, 95% CI 0.4-1.8, P=0.69) compared to those on no 
anticoagulant therapy. In this study, anticoagulant therapy was underused among high-risk 
elderly patients with AF compared to their younger counterparts. Elderly patients had higher 
incidence of major bleeding but similar risk of TE compared to younger patients in this 
cohort. 
Our study provides some important findings from the Australian perspective. Despite 
improvements in the use of anticoagulant therapy among high-risk patients with AF over a 
period of time, our findings highlight a gap between the evidence-based risk stratification and 
antithrombotic management pattern among patients with AF in Tasmania. In the absence of 
contemporary local guidelines, there appears to be a need to better support prescribers to 
assist in the identification and quantification of patient risk according to accepted 
international guidelines to optimise thromboprophylaxis and reduce the risk of 
thromboembolic and bleeding complications in this vulnerable patient group. Given the fact 
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that suboptimal oral anticoagulant use in patients with AF and poor compliance with 
guidelines still persist despite a transition to a new era of anticoagulation featuring DOACs, 
these findings remain pertinent. It is also acknowledged that monitoring of the patients newly 
initiated on treatment could play a significant role in minimising fatal bleeding and TE-
related events in these patients. Our findings regarding the predictors of bleeding or TE 
outcomes suggest several risk factors that should be considered as ‘red flags’ when managing 
patients with AF. Patients with these conditions need special attention when managing 
concomitant AF. In fact, these patient groups are a potential target for intervention in future 
AF studies so as to minimise the incidence of bleeding or TE-related hospitalisations. Finally, 
underuse of anticoagulant therapy among high-risk elderly patients could have been 
influenced by the higher bleeding risk in this cohort compared to the younger group. Our 
finding that the elderly cohort were at higher risk of major bleeding due to anticoagulant 
therapy compared to the younger group requires further investigations so as to identify 
associated reasons for such outcome. 
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Chapter 1 Literature Review 
 
1.1 Atrial Fibrillation   
Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder and is 
increasing in incidence and prevalence in aging populations.(1) The electrical impulse that 
triggers a normal cardiac contraction originates at regular intervals in the sinoatrial node, 
usually at a frequency of 60-100 beats per minute. The generated impulse spreads through the 
atria and enters the atrioventricular node. The impulse then propagates over the His-Purkinje 
system and invades all parts of ventricles. After the ventricular activation, contraction of all 
of the ventricular muscle is normally synchronous and haemodynamically effective.(2) In AF 
however, there is uncoordinated atrial activation and consequently ineffective atrial 
contraction.(3-5) The electrocardiogram (ECG) taken during AF includes 1) irregular R-R 
intervals, 2) absence of distinct repeating P waves, and 3) irregular atrial activity.(6) The 
definition of AF based on duration of episodes is shown in Table 1.1.(3, 5, 7)  
 
1.2 Epidemiology of AF 
It is estimated that 1.5-2% of the developed world suffers from AF.(8, 9) AF is known to 
affect 5% of individuals older than 65 years and 10% of those aged older than 80 years.(9) 
The burden of stroke in terms of absolute numbers of people affected around the world is 
increasing, especially in younger age groups and in low-to-middle-income countries.(10) 
 
Table 1.1 Definitions of AF 
Term                  Definition 
Paroxysmal AF  AF that terminates spontaneously or with intervention within 7 days of 
onset. 
Persistent AF  Continuous AF that is sustained >7 days. 
Long-standing persistent AF  Continuous AF >12 month in duration. 
Permanent AF  When the patient and clinician make a joint decision to stop further 
attempts to restore and/or maintain sinus rhythm. 
 Acceptance of AF represents a therapeutic attitude on the part of the 
patient and clinician rather than an inherent pathophysiological attribute of 
AF. 
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 Acceptance of AF may change as symptoms, efficacy of therapeutic 
interventions, and patient and clinician preferences evolve.  
NVAF  AF in the absence of rheumatic mitral stenosis, a mechanical or 
bioprosthetic heart valve, or mitral valve repair. 
AF: atrial fibrillation; NVAF: non-valvular AF 
 
1.3 Risk of stroke in AF 
AF typically coexists with hypertension (HTN), heart failure, coronary artery disease, and 
diabetes mellitus.(9) Importantly, it significantly and independently increases the risk of 
mortality and morbidity due to stroke, thromboembolism (TE) and congestive heart failure 
(CHF).(11) The risk of stroke and TE is increased 4-5 fold by non-valvular atrial fibrillation 
(NVAF) and nearly 15% of all strokes are caused by AF.(12) The risk increases further with a 
previous history of stroke or transient ischaemic attacks (TIA).(13) Thromboembolism in 
patients with NVAF is secondary to emboli arising from the atrial cavities, particularly the 
left atrial appendage.(14) In fact, several mechanisms consistent with the Virchow triad for 
thrombogenesis have been postulated for AF-related stroke: 1) stasis in the left atrium 
causing flow abnormalities; 2) structural heart and vascular disease (e.g., mitral stenosis); and 
3) abnormal coagulation and fibrinolysis.(13)  
 
Strokes related to AF are associated with higher mortality, greater disability, longer 
hospital stays, poorer functional outcome, and lower chance of being discharged home.(15) 
Stroke prevention is therefore a vital component of AF management. All contemporary 
guidelines recommend stroke prophylaxis with antithrombotic agents in people with AF and 
at least one other risk factor for stroke.(7, 16) 
 
1.4 Stroke risk stratification schemes in AF and guideline recommendations 
Risk factor based approaches are used for stroke risk stratification purposes. Among several 
risk stratification models, the CHADS2 [CHF, HTN, age ≥75 years, diabetes and previous 
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stroke or TIA] (17) score has been the most commonly used due to its simplicity and 
endorsement in several widely promulgated practice guidelines.(18) The available guidelines 
during our study time period also suggested the use of CHADS2 score as a preferred stroke 
risk assessment scheme.(4, 16) However, there has been debate on the advantages and 
disadvantages of the CHADS2 score, particularly its non-inclusion of many common stroke 
risk factors (e.g., age 65-74 years, vascular disease, female sex).(19) 
 
In order to improve risk stratification for stroke, overcoming the limitations of 
CHADS2, the CHA2DS2-VASc [CHF, HTN, diabetes, vascular disease (prior myocardial 
infarction (MI), peripheral artery disease or aortic plaque), age 65-74 years, female gender, 
age ≥75 years and previous stroke or TIA or TE] (20) score was introduced. The CHA2DS2-
VASc score includes more of the common stroke risk factors observed in everyday clinical 
practice. The CHA2DS2-VASc score has been validated in multiple cohorts.(21-25) A 
validation study has revealed that with a CHA2DS2-VASc score of 0 the risk was ‘truly low’ 
and no reduction in thromboembolic rate occurred with vitamin K antagonist (VKA) 
treatment, whereas the thromboembolic rate was reduced in VKA-treated patients with 
CHADS2 scores of 0-1 and a CHA2DS2-VASc score of 1.(25) Recent guideline thus 
recommend CHA2DS2-VASc score as a preferred stroke risk stratification tool due to its 
advantage in identifying ‘truly low-risk’ (score=0) patients who do not need antithrombotic 
therapy.(6, 7) The CHADS2 score is, however, less discriminatory for ‘truly low risk’ patients 
with AF in whom anticoagulation may be associated with a net disadvantage.(26) In 
summary, CHA2DS2-VASc is now established as being superior to the CHADS2 score in 
identifying the ‘truly low risk’ subjects with AF, and as good as CHADS2 score in predicting 
the ‘high risk’ subjects.(27) Table 1.2 shows the two different stroke risk stratification 
schemes. 
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Guidance currently varies on the preferred option for stroke prevention when the 
CHA2DS2-VASc score=1 (for males); some of the recent guidelines however recommend an 
anticoagulant over single or multiple antiplatelet therapy.(6, 7) Truly low-risk patients with 
AF - essentially a CHA2DS2-VASc score=0 (males) or 1 (females with no other predisposing 
risk factors) - do not require antithrombotic therapy, while other patients with the score ≥1 
should have an oral anticoagulant (OAC) as the preferred option (well-controlled warfarin or 
one of the new OAC drugs).(28) Guideline recommendations for stroke prophylaxis based on 
stroke risk scores are summarised in Table 1.3. 
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Table 1.2 Scoring the risk of thromboembolic complications in AF (6) 
Definition and scores for CHADS2 and 
CHA2DS2-VASc 
 
Stroke Risk Stratification With the CHADS2 and CHA2DS2-VASc 
Scores 
                                                  Adjusted Stroke Rate (% per y) 
CHADS2 Score CHADS2  
Congestive HF 1 0 1.9 
Hypertension 1 1 2.8 
Age ≥75 years 1 2 4.0 
Diabetes mellitus 1 3 5.9 
Stroke/TIA/TE 2 4 8.5 
Maximum score 6 5 12.5 
  6 18.2 
CHA2DS2-VASc  CHA2DS2-VASc  
Congestive HF 1 0 0 
Hypertension 1 1 1.3 
Age ≥75 years 2 2 2.2 
Diabetes mellitus 1 3 3.2 
Stroke/TIA/TE 2 4 4.0 
Vascular disease (prior 
MI, PAD, or aortic 
plaque) 
1 5 6.7 
Age 65-74 years 1 6 9.8 
Sex category (i.e., 
female sex) 
1 7 9.6 
Maximum score 9 8 6.7 
  9 15.20 
AF: atrial fibrillation; HF: heart failure; MI: myocardial infarction; PAD: peripheral artery disease; TE: 
thromboembolism; and TIA: transient ischaemic attack 
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Table 1.3 Guideline recommendations for stroke prophylaxis based on stroke risk scores 
Guideline Preferred scoring 
method 
Values Recommendation 
ESC 2010 (4) CHADS2 0 
 
 Either aspirin or no antithrombotic 
therapy. Preferred: no antithrombotic 
therapy rather than aspirin 
  1  Either OAC or aspirin Preferred: OAC 
rather than aspirin 
  ≥2  OAC, either VKA or DOACs 
ACCP 2012 (16)  CHADS2 0 
 
 Either aspirin alone or combination of 
aspirin and clopidogrel. Preferred: no 
antithrombotic therapy than antiplatelet 
agents 
  1  OAC instead of no therapy or antiplatelet 
therapy 
  ≥2  OAC (either VKA or DOACs) instead of no 
therapy or antiplatelet therapy 
AHA/ACC/HRS 2014 (6) CHA2DS2-VASc 0  No antithrombotic therapy 
  1  No therapy, or treatment with OAC or 
aspirin may be considered 
  ≥2  OAC, either VKA or DOACs 
ESC 2012 (7) CHA2DS2-VASc 0  No antithrombotic therapy 
  1  Consider OAC for men, assess HAS-BLED 
score 
  ≥2  Offer OAC, assess HAS-BLED score 
NICE 2014 (29) CHA2DS2-VASc 0  No antithrombotic therapy 
  1  Consider OAC, discuss options with 
patients 
  ≥2  Offer OAC, discuss options with patients 
CCS 2014 (30) CHADS2 (age ≥65 
and vascular 
diseases are 
considered) 
0 
 
 No therapy, but aspirin is suggested for 
patients aged <65 years and with vascular 
disease 
  ≥1  Female sex and vascular disease are not 
considered as sufficient reasons for OAC 
use  
 OAC should be used, including in patients 
aged ≥65 years and without other risk 
factors 
ACCP: American College of Chest Physicians; AHA/ACC/HRS: American Heart Association/American College of 
Cardiology/ Heart Rhythm Society; CCS: Canadian Cardiovascular Society; DOACs: direct oral anticoagulants; ESC: 
European Society of Cardiology; NICE; National Institute for Health and Clinical Excellence; OAC: oral anticoagulants; 
VKA: vitamin K antagonists  
 
1.5 Bleeding risk stratification in AF 
It is important to evaluate bleeding risk in patients with AF, especially in cases in which 
antithrombotic therapy is being prescribed.(31) The decision to prescribe thromboprophylaxis 
needs to balance the risk of stroke against the risk of bleeding. Intracranial haemorrhage 
(ICH) is the most feared complication of anticoagulation therapy and confers a high risk of 
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death and disability.(32) The HAS-BLED [HTN, abnormal renal function, abnormal liver 
function, bleeding pre-disposition, age >65 years, the use of drugs predisposing patients to 
bleeding (non-steroidal anti-inflammatory drugs (NSAIDs)), alcohol use (>8 drinks per 
week), previous stroke and labile INRs] is a recently proposed bleeding risk score - see Table 
1.4.(33) 
 
Table 1.4 Clinical Characteristics Composing the HAS-BLED Bleeding Risk Score 
HAS-BLED Score 
Hypertension 1 
 
Abnormal renal and liver function (1 point each) 1 or 2 
 
Stroke 1 
 
Bleeding 1 
 
Labile INRs (e.g., TTR <60%, applies only if the patient 
is taking warfarin) 
 
1 
 
Elderly (age >65  years) 1 
 
Drugs or alcohol (1 point each) 1 or 2 
 
Maximum 9 points 
INR: international normalised ratio; TTR: time in therapeutic range 
 
The HAS-BLED score helps clinicians to make an informed assessment of bleeding 
risk. It has been validated in several independent cohorts (33-37) and correlates well with 
ICH risk. A formal bleeding risk assessment is recommended for all patients with AF and, in 
patients with a HAS-BLED score ≥3, caution and regular review are recommended.(7) As a 
general rule, OACs should be considered for all patients with AF, except those at very low 
risk for stroke (CHA2DS2-VASc score of 0) and those at extremely high risk for bleeding, so 
as to avoid the risk of unwanted bleeding.(38)  
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1.6 Antithrombotic therapy in AF 
Stroke prevention is imperative to the management of AF. Without antithrombotic treatment, 
the annual risk of stroke in patient with NVAF increases from 5% in patients aged less than 
65 years to 8% in patients 75 years of age or older.(39) Contemporary guidelines recommend 
prophylaxis with antithrombotic agents in people with AF and at least one other risk factor 
for stroke.(7, 16) A flowchart on how to choose antithrombotic therapy in patients with AF 
based on a guideline recommendation is shown in Figure 1.1.(7) A meta-analysis by Hart 
(40) revealed that judicious use of antithrombotic therapy reduces stroke for most patients 
who have AF. Options include the older antithrombotic drugs like warfarin, aspirin, and 
clopidogrel as well as the newer direct thrombin inhibitors and factor Xa inhibitors. Ideal 
anticoagulants should be efficacious, safe, and cost effective. The choice between these drugs 
for an individual patient depends on the existing clinical scenario and the patient’s long-term 
risk of stroke. Thromboembolic risk factors due to AF and risk factors for bleeding due to 
oral antithrombotic therapy are largely the same, and bleeding risk very rarely outweighs the 
benefits of thrombosis prevention; hence, antithrombotic therapy is beneficial in almost all 
patients with AF.(26, 41, 42)  
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Oral anticoagulant therapy 
Assess bleeding risk 
(HAS-BLED score) 
Consider patient values 
and preferences 
NOAC VKA No antithrombotic 
therapy 
1 
Yes 
<65 years and lone AF (including females) 
Assess risk of stroke 
(CHA2DS2-VASc score) 
≥2 
No 
0 
No (i.e. non-valvular AF) 
Yes 
AF 
Valvular AF
a
 
 Figure 1.1: Choice of anticoagulant in AF 
AF: atrial fibrillation; NOAC: non-VKA-oral anticoagulant; OAC: oral anticoagulant; 
VKA: vitamin K antagonist. 
a Includes rheumatic valvular disease and prosthetic valves 
Line: solid = best option; dashed = alternative option. 
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1.6.1 VKAs - Warfarin 
Warfarin is known to exert its anticoagulant effect by inhibiting gamma-glutamyl 
carboxylation of vitamin K-dependent clotting factors II, VII, IX and X. The blockade results 
in incomplete coagulation factor molecules that are biologically inactive. Warfarin mainly 
prevents reductive metabolism of the inactive vitamin K epoxide back to its active 
hydroquinone form as shown in Figure 1.2.(2)  
 
 
Figure 1.2: Mechanism of action of warfarin 
KH2: reduced vitamin K; KO: oxidised vitamin K 
 
Despite the convincing evidence for the use of warfarin in AF, it is frequently reported as 
being underutilised.(43) Underuse of antithrombotic therapy is associated with an increase in 
the rate of death and ischaemic events, and increased overall health care costs.(44, 45) 
Improving the utilisation and adherence to OAC has been shown important to attaining the 
clinical and economic benefits of therapy.(45) Underuse of warfarin is often associated with 
its inherent pharmacological limitations, as listed below and requiring close monitoring:  
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1. Narrow therapeutic index, 
2. Slow onset and offset of action, 
3. Unpredictable pharmacodynamic and pharmacokinetic profiles, and  
4. Multiple drug and food interactions. 
 
Issues appear to exist with the quality of anticoagulation management with warfarin in 
long term use, because of fluctuations of INR values, due to multiple factors like genetic 
factors, poor compliance with medication, drug-drug interactions, and changes in diet.(46) 
For safe and effective stroke risk reduction with warfarin, the INR needs to be maintained in 
the range of 2.0-3.0 for at least 60% of the time.(47) Time in therapeutic range (TTR) is 
highly correlated with clinical outcomes; a poor TTR (<60%) is strongly associated with 
higher rates of mortality and major bleeding compared with moderate (60-75%) and good 
control (>75%).(48) A review has found that in patients with AF, a 7% improvement in TTR 
is associated with one less haemorrhagic event per 100 patient-years and a 12% improvement 
is associated with one less TE event per 100 patient-years.(49) A recent study conducted 
across western Europe revealed that overall anticoagulation management according to TTR 
was relatively homogenous and well-controlled in patients with AF, ranging from 70.3% in 
Spain to 81.4% in Germany.(50) However, the story may be different in developing countries. 
Data on the quality of anticoagulation achieved in developing countries was provided by the 
RE-LY trial (51), where the mean TTR was 56.9% for developing countries and 65.4% for 
developed countries. The mean TTR in 70.6% of developing countries represented in this trial 
(as classified by the World Bank (52)) demonstrated poor TTRs (<60%) or labile INRs, in 
contrast to the developed countries, where 81.5% of the participating countries obtained 
moderate TTRs (60-75%). Table 1.5 shows the TTRs of developed and developing countries 
in the same trial.  
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There are limited data available regarding INR control in Australia. The Commonwealth 
Review of Anticoagulation Therapies in AF in Australia identified the need to establish 
current warfarin control and determine the potential place of the new oral anticoagulants.(53) 
A retrospective study (54) conducted among 1137 patients to determine the quality INR 
control in southern Tasmania revealed that this group had a mean TTR of 69.1% and a mean 
testing interval of 22.9 days. The proportion of patients with a mean TTR <60% was 22.3% 
and 52.5% had a TTR >70%. This revealed better real world INR control in Tasmania 
compared to clinical trial results. Another retrospective study conducted to investigate the 
influence of pharmacist-led medication reviews on INR control in elderly patients in 
Tasmania observed the overall TTR of 64% and this was comparable to that achieved in 
recent randomised trials involving warfarin.(55) A  recently conducted study among 3692 
patients to determine warfarin control by a pathology practice in Queensland, Australia and 
identify factors influencing TTR observed a mean TTR of over 81% with 97% of patients 
above a TTR of 60%. TTR was not significantly influenced by age, gender or socioeconomic 
factors in this study.(56) These data demonstrate that dedicated warfarin programs can 
produce high quality care ensuring the full benefit of warfarin for Australian patients.(56)  
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Table 1.5 Quality of INR control in developed and developing countries in the RE-LY trial (51) 
 
Time in therapeutic range 
(TTR) 
 
Developed countries (n=27/44) 
 
Developing countries (n=17/44) 
 
<60% (poor) 
 
 
 
4 (14.8%) 
 
12 (70.6%) 
 
60-75% (moderate) 
 
 
22 (81.5%) 
 
5 (29.4%) 
 
>75% (good) 
 
 
1 (3.7%) 
 
0 
INR: international normalised ratio 
 
While it is acknowledged that comparison of TTR results has limitations associated 
with large variations in site performance and that this may be even more significant in 
developing countries due to the lack of standard disease management guidelines these data 
nevertheless illustrate the disparity in INR control between the developed and developing 
world, especially in the absence of more comprehensive indicators of anticoagulation quality 
(e.g. risk-adjusted TTR).(57) These results are significant as modelling has suggested that a 
minimum TTR threshold of 58% is necessary for a positive risk-benefit balance with warfarin 
use in AF (58); below this threshold, warfarin may result in poorer outcomes than antiplatelet 
therapy. This association between TTR and clinical outcomes was also apparent in the RE-
LY study - rates of stroke and TE, as well as major bleeding, were greater among patients 
receiving warfarin with a TTR below 50%. Compared to dabigatran, warfarin was more cost-
effective only when patients’ TTR was greater than 72%.(51)   
 
To overcome the limitations of warfarin, a number of direct oral anticoagulants 
(DOACs) are under development or have been marketed. Switching from warfarin therapy to 
DOACs is however advocated only if INR control has been poor or if frequent monitoring is 
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problematic.(59) Hence, the choice of agent should be dictated by a risk-benefit analysis 
based on an individual patient’s characteristics. 
 
1.6.2 DOACs 
The DOACs for stroke prevention in AF fall into two classes: the oral direct thrombin 
inhibitors (dabigatran) and oral direct factor Xa inhibitors (rivaroxaban, apixaban and 
edoxaban).(60) DOACs selectively block the formation of factor IIa and Xa, respectively, as 
shown in Figure 1.3.(2) DOACs are recommended when VKAs cannot be used because of 
difficulty in maintaining a therapeutic INR, adverse drug reactions, and inability to attend 
INR monitoring.(61) Though there is lack of head-head trials comparing the use of particular 
DOACs, specific recommendations for dabigatran etexilate and rivaroxaban are provided in 
the European guideline of 2012.(7)  
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Figure 1.3: Mechanism of action of DOACs 
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1.6.2.1 Oral direct thrombin inhibitors 
Dabigatran 
Dabigatran etexilate is a prodrug of dabigatran. Dabigatran is a potent, highly specific, 
competitive, oral thrombin inhibitor that acts specifically both on bound and free 
thrombin.(62) The prodrug form of dabigatran etexilate is converted by serum esterases to the 
active drug dabigatran, thus making the prodrug form independent of CYP450 for the 
conversion, which ultimately makes drug-drug and drug-diet interactions less likely though 
some of them have been reported.(63, 64) Bioavailability of orally administered dabigatran is 
estimated to be about 6%, requiring relatively high doses for maintaining therapeutic plasma 
concentrations.(63) Use of dabigatran requires a rational dose individualisation and 
monitoring guidance particularly among patients at high risk of bleeding such as the elderly, 
overweight patients, and those with renal impairment (avoided in those with severe renal 
impairment: GFR <30ml/min) and/or on drugs with potential interactions.(65) The results of 
the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) (66) trial 
showed that dabigatran administered at a dose of 150mg given twice daily, as compared with 
warfarin, was associated with lower rates of stroke and systemic embolism (SE) but similar 
rates of major haemorrhage. On the other hand, the dosage regimen of 110mg given twice 
daily was shown to be non-inferior to warfarin with less incidence of bleeding. 
 
1.6.2.2 Oral factor XA inhibitors 
Rivaroxaban 
Rivaroxaban is an oral factor Xa inhibitor, which is competitive and reversible in its 
mechanism and has a rapid onset of action and dose dependent pharmacokinetics and 
pharmacodynamics.(67-69) It attains peak plasma concentration in about 3 hours and has a 
bioavailability of 60-80%; it has terminal half-life of 5-9 hours in young individuals and 
approximately 11-13 hours in people older than 75 years.(69, 70) The phase III study 
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Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K 
antagonists for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) 
(71) revealed that rivaroxaban was similar to warfarin for the primary efficacy endpoint of 
prevention of stroke and SE. 
 
Apixaban 
Apixaban is also a reversible, direct, and highly selective inhibitor of factor Xa. Apixaban 
and its metabolites are excreted by multiple elimination pathways, including renal excretion 
and metabolism. This suggests that patients with hepatic or renal impairment may be treated 
with apixaban and that the likelihood of significant drug-drug interactions may be low.(72) 
  
The AVERROES (Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in 
Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonists 
Treatment) (73) study was designed to determine the efficacy and safety of apixaban as 
compared to aspirin for the treatment of patients with AF for whom VKA therapy was 
considered unsuitable. The trial was stopped early due to significant reduction in the primary 
endpoint stroke or SE with apixaban (1.6% per year) compared to aspirin (3.7% per year). 
There was no significant difference in rates of major bleeding or ICH between apixaban 
(1.4% per year) and aspirin (1.2% per year). Another trial, Apixaban for Reduction in Stroke 
and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) (74) comparing 
apixaban to warfarin found apixaban to be superior to warfarin at a dose of 5mg twice daily, 
significantly reducing the risk of stroke or SE by 21% and major bleeding by 31%. 
 
Edoxaban 
Edoxaban is an oral, direct and reversible factor Xa inhibitor.(75) The Effective 
Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation- Thrombolysis In 
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Myocardial Infarction 48 (ENGAGE AF-TIMI 48) (76) trial compared once daily low 
(30mg) and high dose (60mg) edoxaban to warfarin. High dose edoxaban was found to be 
non-inferior with respect to prevention of stroke or SE, with the same rate of ischaemic stroke 
as warfarin.  
 
There are considerable differences in pharmacodynamic and pharmacokinetic 
properties between the individual DOACs.(77) Differences in the pharmacological properties 
of DOACs are shown in Table 1.6.(78) Comparison of the characteristics of the patients 
enrolled in different trials of DOACs is shown in Table 1.7.  
  
Table 1.6 Pharmacological properties of DOACs 
Characteristics Dabigatran Rivaroxaban Apixaban Edoxaban 
Direct target Factor IIa (thrombin) Factor Xa Factor Xa Factor Xa 
Need for monitoring No No No No 
Pro-drug Yes No No No 
Bioavailability ≈6% >80% ≈50% ≈50% 
Time to reach peak 
plasma 
concentration 
(hours) 
2-3 2-3 2-3 1-2 
Half-life (hours) 14-17 5-13 8-15 6-11 
Metabolism P-gp P-gp 
CYP3A4/3A5 
CYP2J2 
P-gp 
CYP3A4/3A5 
 
P-gp 
CYP3A4 
Renal elimination >80% ≈50% ≈50% ≈50% 
P-gp: P-glycoprotein 
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Table 1.7 Patient characteristics comparison between warfarin vs. DOACs clinical trials 
Patient characteristics RELY-AF (66) 
(n=18,113) 
ROCKET AF (71) 
(n=14,264) 
ARISTOTLE (74) 
(n=18,201) 
ENGAGE-TIMI (76) 
(n=21,105) 
Age in years 72 73 70 72 
Males (%) 64 60 65 62 
Comorbidities (%)     
CHF 32 62 35 58 
HTN 79 90 87 94 
Diabetes 23 40 25 36 
Prior stroke/TIA 20 55 20 28 
Prior MI 17 17 14 - 
History of bleeding - - - - 
AF type NVAF NVAF NVAF NVAF 
New-onset AF - 1.4% - - 
Mean CHADS2 2.1 3.5 3.5 2.8 
Mean CHA2DS2-VASc - - - - 
AF: atrial fibrillation; CHF: congestive heart failure; HTN: hypertension; MI: myocardial infarction; TIA: transient 
ischaemic attack 
 
1.6.3 Antiplatelet therapy 
1.6.3.1 Aspirin 
Aspirin inhibits the synthesis of thromboxane A2 by irreversible acetylation of the enzyme 
cyclooxygenase.(2) A meta-analysis by Hart (40) revealed that warfarin was more efficacious 
than antiplatelet therapy; adjusted-dose warfarin and antiplatelet agents reduced stroke by 
approximately 60% and 20%, respectively, in patients with AF. Antiplatelet therapy has 
limited utility for stroke prevention as the risk of bleeding is not different between aspirin and 
warfarin.(34, 41, 79) The efficacy of warfarin as prophylaxis against stroke and its benefits 
over antiplatelet therapies are well established.(80) Aspirin is only recommended for stroke 
prevention where patients refuse anticoagulation, and preferably given in combination with 
clopidogrel.(7)  
 
1.6.3.2 Clopidogrel 
Clopidogrel is a thienopyridine derivative that reduces platelet aggregation by inhibiting the 
adenosine diphosphate (ADP) pathway of platelet. It irreversibly blocks the ADP receptor on 
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platelet.(2) There is no evidence to support the use of clopidogrel monotherapy over aspirin 
or OAC in AF.(81)  
 
1.6.3.3 Combination antiplatelet therapy 
Studies have found that aspirin-clopidogrel combination therapy has additional efficacy as 
compared to aspirin monotherapy; however, the combination increases the risk for major 
bleeding.(82) The Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of 
Vascular Events (ACTIVE-W) was a trial involving comparison of combination antiplatelet 
therapy (clopidogrel and aspirin) with warfarin. It was stopped early due to the clear evidence 
of superiority of OAC therapy, with the annual stroke risk on warfarin of 3.93% compared 
with annual stroke risk on clopidogrel plus aspirin of 5.6%.(81) 
 
1.6.4 Anticoagulation plus antiplatelet therapy 
The combination of fixed dose warfarin (INR 1.3) plus aspirin was found to be significantly 
inferior to full dose anticoagulation (INR 2-3) in Stroke Prevention in Atrial Fibrillation 
(SPAF) III trial.(83) Trials testing the combination of anticoagulation plus antiplatelet 
therapy have shown mixed results and there is absence of clear evidence for the benefit of 
combination therapy with full anticoagulation.(84)  
 
Some of the studies have shown increases in the risk of haemorrhage with 
combination therapy of anticoagulation and antiplatelet agents.(85-87) Guidelines clearly 
mention that the usefulness of combination OAC and antiplatelet therapy particularly applies 
in patients with AF and acute coronary syndromes (ACS) or to those having percutaneous 
coronary intervention or stenting for up to 12 months after the procedure. However, for 
patients with AF and stable coronary artery disease only OAC is recommended rather than 
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combination of OAC and aspirin as combination therapy is associated with a significantly 
higher risk of bleeding.(16) 
 
1.6.5 DOACs versus Warfarin 
Dabigatran, rivaroxaban, apixaban and edoxaban have been compared to warfarin in patients 
with AF in four pivotal clinical trials.(66, 71, 74, 76) The data from these trials indicated that, 
generally, the DOACs are at least noninferior to warfarin in regards to the primary outcomes 
of stroke/SE and major bleeding, and are superior to warfarin with respect to the rate of 
intracranial bleeding and haemorrhagic stroke. The summary of phase III randomised clinical 
trials for DOACs is shown in Table 1.8. Most of these clinical trials involving DOACs have 
been conducted in developed countries, and their rapid uptake to date suggests that they will 
most likely displace warfarin in these countries in the near future.(88) However, developing 
countries may have more difficulties in adopting these drugs into practice. Issues related to 
the safety, efficacy and cost-effectiveness of DOACs could be the major hurdle for their 
approval in the developing world. Until further safety and efficacy data emerge, warfarin and 
aspirin are likely to continue as first line antithrombotic agents.  
 
In a meta-analysis of 50,578 patients from 3 randomised trials that compared DOACs 
with warfarin in AF, it was found that DOACs decreased stroke or SE, haemorrhagic stroke 
and mortality, with a similar risk of major bleeding compared to warfarin.(89) DOACs were 
associated with lower rates of haemorrhagic stroke (0.3% vs. 0.8%, odds ratio (OR) 0.79, 
95% CI 0.71-0.88, P<0.001) and intracranial bleeding (0.6% vs. 1.3%, P<0.001), and a higher 
rate of gastrointestinal bleeding (GIB) (2.3% vs. 1.3%, P=0.036). A systematic review (90) 
that compared the effectiveness of warfarin and DOACs for the management of AF and 
venous TE considered DOACs as a viable option for patients receiving long-term 
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anticoagulation. DOACs decreased all-cause mortality (risk ratio [RR], 0.88 [95% CI, 0.82 to 
0.96]) and the adverse effects of DOACs compared with warfarin were fatal bleeding (RR, 
0.60 [CI, 0.46 to 0.77]), major bleeding (RR, 0.80 [CI, 0.63 to 1.01]), GI bleeding (RR, 1.30 
[CI, 0.97 to 1.73]), and discontinuation due to adverse events (RR, 1.23 [CI, 1.05 to 1.44]). 
The review, through its subgroup analysis, also suggested that the bleeding risk for DOACs 
may be increased in persons older than 75 years or those who had been receiving warfarin 
with good control. Similarly, a Chinese study (91) found that, after 1.9 years of follow-up, 
there was suboptimal or lower quality stroke prevention among 1034 patients with AF, with 
no difference between antiplatelet- and OAC-treated patients. Modelling analyses concluded 
that the use of apixaban or dabigatran could provide better stroke prevention compared to 
antiplatelet or warfarin use, with a positive net clinical benefit. A hospital-based Malaysian 
retrospective study (92), conducted among 510 patients between 2010 and 2013 to investigate 
the safety and efficacy of dabigatran in AF, found lower rates of ischaemic stroke, side effects 
and bleeding with dabigatran than in the RE-LY trial, and a high patient preference to switch 
from warfarin. These results provide reassurance that DOACs can be safer than warfarin, if 
prescribed appropriately. 
 
A population-based descriptive analysis study (88)  that looked into the prescribing 
patterns of DOACs following regulatory approval for AF in Ontario, Canada, between 
October 2010 and September 2012 found rapid growth in the uptake of DOACs, particularly 
dabigatran. The monthly prescriptions of DOACs increased more than 20-fold, from 16 to 
336 prescriptions per 1000 000 population. Most of the dabigatran prescriptions were for the 
lower dosage (110 mg/d) in the older patient groups (58.8% of prescriptions in the 65-84 age 
group and 93.6% in the oldest group). This growth in the uptake of DOACs in very old 
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patients (i.e. those at the highest risk of bleeding) cautioned the need to evaluate outcomes in 
clinical practice to better guide the use of these drugs.  
 
Despite the proven benefits of DOACs, there still remains significant uncertainty 
about the safety, effectiveness and cost-effectiveness of DOACs in widespread clinical 
use.(53) There have been reports of deaths related to dabigatran internationally.(93, 94) There 
is a need for ongoing clinical trials and real-world based observational studies to gather more 
information about DOACs. Few real-world based observational studies have been conducted 
in relation to comparing the safety and efficacy profile of warfarin vs. DOACs.(95-99) 
Several registries have also been established so as to generate important data regarding AF 
management practices in the real-world. Comparison of patient characteristics among some 
of these registries has been shown in Table 1.9. Summary of data regarding the outcomes of 
treatment relating to warfarin vs. DOACs in some of the observational real-world studies and 
registries have been shown in Table 1.10. A recent review of longitudinal observational 
studies comparing dabigatran with warfarin, summarised that, in real-world clinical practice, 
dabigatran was comparable with warfarin in preventing ischaemic stroke among patients with 
NVAF. However, dabigatran was found to have lower risk of intracranial bleeding relative to 
warfarin, but, particularly among elderly, a greater risk for GIB.(100)      
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Table 1.8 Clinical trials comparing Safety and efficacy outcomes of DOACs with warfarin in patients with 
NVAF (101, 102) 
TRIAL  RE-LY (66) 
DABIGATRAN  
ARISTOTLE (74) 
APIXABAN  
 
ROCKET-AF (71) 
RIVAROXABAN 
ENGAGE AF –TIMI 48 (76) 
EDOXABAN 
Number of patients 18,113 18,201 14,000 21,105 
Design Open-labelled, non-inferior Double-blind, 
double dummy, 
non-inferiority  
Double-blind, 
double dummy, 
non-inferiority 
Double-blind, double 
dummy 
Drug and dosages Dabigatran 
110mg twice 
daily versus 
warfarin 
Dabigatran 
150mg twice 
daily versus 
warfarin 
Apixaban 5mg 
twice daily versus 
warfarin 
Rivaroxaban 20mg 
once daily versus 
warfarin 
Higher-
dose 
edoxaba
n versus 
warfarin 
Lower-dose 
edoxaban 
versus 
warfarin 
Primary end point 
(% per year ) stroke 
or SE 
1.53% vs 
1.69% 
p=0.34 
1.11% vs 
1.69% 
p<0.001 
1.27% vs 1.60% 
p=0.01 
2.12% vs 2.42% 
p=0.117 
1.57% vs 
1.80% 
p=0.08 
2.04% 
vs  1.80% 
p=0.10 
Ischaemic stroke 
(or unspecified) 
1.34% vs 
1.20%  
p=0.35 
0.92% vs 
1.20 
p=0.03 
0.97% vs 1.05% 
p=0.42 
1.34% vs 1.42% 
p=0.581 
1.25% vs 
1.25% 
p=0.97 
1.77% vs 
1.25% 
p<0.001 
Haemorrhagic 
stroke 
0.12% vs 
0.38%  
p<0.001 
0.10% vs 
0.38%  
p<0.001 
0.24% vs 0.47% 
p<0.001 
0.26% vs 0.44%  
p=0.024 
0.26% vs 
0.47% 
p<0.001 
0.16% vs 
0.47% 
p<0.001 
Intracranial 
haemorrhage 
0.23% vs 
0.74%  
p<0.001 
0.30% vs 
0.74% 
p<0.001 
0.33% vs 0.80% 
p<0.001 
0.49% vs 0.74%  
p= 0.019 
0.39% vs 
0.85% 
p<0.001 
0.26% vs 
0.85% 
p<0.001 
Major bleeding 2.71% vs 
3.36% 
p=0.003 
3.11% vs 
0.74% 
p<0.001 
2.13% vs 3.09% 
p<0.001 
3.6% vs 3.45%  
p=0.576 
2.75% vs 
3.43% 
p<0.001 
1.61% vs 
3.43% 
p<0.001 
Gastrointestinal 
bleeding 
1.12% vs 
1.02% 
p=0.43 
1.51% vs 
1.02% 
p<0.001 
0.76% vs 0.86% 
p=0.37 
3.15% vs 2.16% 
p<0.001 
1.51% vs 
1.23% 
p=0.03 
0.82% vs 
1.23% 
p<0.001 
All-cause death 3.75% vs 
4.13% 
p=0.43 
3.64% vs 
4.13% 
p=0.051 
3.52% vs 3.94% 
p=0.046 
1.87% vs 2.21% 
p=0.073 
3.99% vs 
4.35%  
p=0.08 
3.80% vs 
4.35% 
p=0.006 
Vascular death 2.43% vs 
2.69% 
p=0.21 
2.28% vs 
2.69% 
p=0.04 
1.80% vs 2.02% 
p>0.05 
1.53% vs 1.71%  
p=0.289 
- - 
Drug 
discontinuation 
rate  
21.2% vs 
16.6% 
20.7% vs 
16.6% 
25.3% vs 27.5% 23.9% vs 22.4% - - 
AF: atrial fibrillation; DOACs: direct oral anticoagulants; NVAF: nonvalvular atrial fibrillation; SE: systemic 
embolism
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Table 1.9 Patient characteristics comparison with contemporary AF registries 
Patient 
characteristics 
GARFIELD-
AF (103) 
(n=10,614
) 
ORBIT-
AF (104) 
(n=9957) 
Fushimi 
AF 
Registry 
(105) 
(n=3183) 
RecordAF 
(106) 
(n=5604) 
 
Stockholm 
AF 
database 
(107) 
(n=43, 353) 
J-RHYTHM 
(108) 
(n=7,937) 
GLORIA-AF 
(109) 
(n=10,675) 
Realise-AF 
(110) 
(n=10,523) 
EORP-AF 
(111) 
(n=3049) 
ORBIT-
AF II 
(112) 
ATRIUM (113) 
(n=3,667) 
Age in years 70.2 75 74.2 66 - 69.7 71.0 66.6 68.8 73 72 
Men (%) 56.8 58.0 59.3 57 56 68. 9 54.5 56.4 59.6 56  
Comorbidities 
(%) 
           
CHF 21.0 32.1 27.9 26 
(n=5,600) 
37.3 - 23.7 45.8 47.5 23 43 
HTN 77.8 83.0 60.6 68 
(n=5,601) 
64.9 59.1 74.9 72.2 70.9 83 84 
Prior 
stroke/TIA 
14.4 15.0 21.8 6 
(n=5,572) 
4 
(n=5,540) 
24.1 
(stroke/TIA
/SE) 
14 9.4 14.1 10.5 11 20 
Diabetes 22 29.4 23.2 16 
(n=5,600) 
19.7 18.2 23.0 21.3 20.6 27 35 
MI - 16 6.4 9 
(n=5,560) 
- - 10.5 
 
- 44.8 34 - 
History of          
bleeding 
3.5 - 1.7% - - - 5.7 - 5.9 - - 
PVD 7.0 - - 3 
(n=5,487) 
34.1  -  - 11.2 - - 
Mean CHADS2 1.9 - 2.09 - - 1.7 - - - 2 2.2 
Mean 
CHA2DS2-VASc 
3.2 - 3.43 - 3.82 - - 
 
- 3.2  3.8 
Mean HAS-
BLED 
- - - - - - 1.4 -          1.4  - 
AF: atrial fibrillation; CHF: congestive heart failure; HTN: hypertension; MI: myocardial infarction; PVD: peripheral vascular disease; SE: systemic embolism; TIA: transient 
ischaemic attack  
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Table 1.10 Summary of real-world studies relating to warfarin versus DOACs 
 
CVA: cerebrovascular accident; DOACs: direct oral anticoagulants; SE: systemic embolism; VKA: vitamin K antagonist 
 
Research group, 
year  
DOACs VKAs Follow-up Summary of bleeding and TE outcomes 
Sorensen et al (98) 
(2011) 
 
Dabigatran 110mg 
(n=1612) 
Dabigatran 150mg 
(n=1114) 
VKA (n=49640) 
 
August 22-
December 31, 2011 
 Increased risk of TE and bleeding 
with dabigatran among previous VKA users 
 With cautious interpretation, 
dabigatran use in VKA naive patients seemed 
safe.  
Southworth MR et 
al (97) (2013) 
 
Dabigatran Warfarin October 2010 to 
December 2011 
 Bleeding rates associated with 
dabigatran was not higher than those with 
warfarin, a finding that was consistent with 
the results of RE-LY 
Larsen et al (95) 
(2013) 
 
Dabigatran 
(n=4,978) 
Warfarin 
(n=8,936) 
10.5 months  Similar stroke/SE and major 
bleeding rates with dabigatran (both doses) 
compared with warfarin 
Berger R et al (96) 
(2013) 
Dabigatran (n=15) Warfarin (n=123) 6 months  Fewer ICH in patients receiving 
dabigatran than warfarin 
Yap LB et al (99) 
(2015) 
Dabigatran (n=500) Warfarin (n=500) 315±280 days  Similar rates of efficacy for 
outcomes of ischaemic CVA, and bleeding 
Kodani E et al (114) 
(2016) 
DOACs (n=923) Warfarin (n=3,964) 5 years  DOACs was identified as a potential 
beneficial for reducing event rates of all types 
in Japanese NVAF patients 
Korenstra J et al 
(115) (2016) 
Dabigatran (n=442) Acenocoumarol 
(n=478) 
2010 to 2013  Dabigatran appeared to be as 
effective, but significantly safer than 
acenocoumarol 
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1.7 Underutilisation of antithrombotic therapy in AF 
All contemporary guidelines recommend stroke prophylaxis with antithrombotic agents in 
people with AF and at least one other risk factor for stroke.(7, 16) Despite this 
recommendation, anticoagulation is underused in patients with AF.(116, 117) A recent 
review (118) has identified that suboptimal use of anticoagulants particularly in a patients 
with a high risk of stroke, is a persisting challenge despite the availability of DOACs. The 
Garfield registry which is a prospective, multicentre, international registry of patients newly 
diagnosed with AF, has shown OACs are used inappropriately in a large proportion of AF 
patients.(119) A systematic review by Ogilvie et al (116) has highlighted suboptimal 
treatment of high risk patients with AF. In the majority of the studies they reviewed, patients 
with AF and prior stroke or TIA were found undertreated with OACs. Consequently, 
underuse of antithrombotic therapy is associated with an increase in the rate of death and 
ischaemic events (stroke, TIA, or MI).  
 
There could be multiple reasons for underuse of oral anticoagulation;(120-123) some 
of them include low levels of therapy initiation, and the narrow therapeutic margin (INR ratio 
2-3 in NVAF) leading to low patient compliance.(121) Inconvenience (124) and physicians’ 
concern over haemorrhage were found to be other main reasons for the underuse of 
antithrombotic therapy in AF.(125-127) In a systematic review by Neidecker (128) physician 
surveys revealed the factors for not prescribing warfarin to be risk of falls, dementia, short 
life expectancy, and history of bleeding. In a study by Margaret et al conducted to track 
longitudinal warfarin use using pharmacy and laboratory databases, (129) out of 4188 
warfarin initiated patients, 26.3% of the subjects discontinued therapy within 1 year of after 
warfarin initiation. Most of the patients to do so were aged <65 years, patients with poorer 
anticoagulation control and patients with lower stroke risk (CHADS2 score of 0 compared to 
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4 to 6). Another study, carried among 651 patients on OACs after ischaemic stroke observed 
a 22% discontinuation rate after 1 year. Bleeding was the main reason for discontinuation and 
‘patient request’ or ‘hassle to visit anticoagulation clinic’ were explanations for others.(130) 
A recent study conducted among elderly patients in Germany also revealed that a 
considerable proportion of AF cases did not receive antithrombotic drugs in routine 
care.(131) 
 
Physicians are reluctant to prescribe warfarin in elderly patients due to high risk of 
falls and risk of traumatic ICH, poor compliance, difficulty in monitoring, cognitive 
impairment and risk of interaction with multiple other drugs.(132, 133) These issues may 
underline possible explanations for the substantial underutilisation of VKAs in the elderly 
population. OAC therapy continues to be underutilised in older adults despite compelling 
evidence of benefits of stroke reduction in the corresponding age group. While the double 
impact of clearer guidance together with the advent of DOACs was expected to increase 
current use of OAC, greatly improving patient outcomes and thus reducing the burden of AF–
related stroke, (134) a recent review has highlighted suboptimal OAC use in patients with AF 
and poor compliance with guidelines still persists despite transition to a new era of 
anticoagulation featuring DOACs.(118) 
 
1.8 Potential use of DOACs: pros and cons  
DOACs do have several advantages over warfarin, as shown in Table 1.11, in terms of stroke 
prophylaxis in AF. There are disadvantages, however, as discussed below. The limitations of 
DOACs must be taken into account when treating patients and prescribers should try to 
maintain vigilance to minimise adverse outcomes. 
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Table 1.11: Advantages and disadvantages of anticoagulants 
 Advantages Disadvantages Relevance  
 
Warfarin 
 
 
 
 Well-known drug    
 Better patient adherence due to once daily 
dosing  
 Antidotes available  
 Indicated in valvular AF  
 Low cost                                               
 
 Narrow therapeutic index 
 Slow onset and offset of action   
 Unpredictable pharmacokinetic/ 
pharmacodynamic effects 
 Multiple drug and food interactions 
 Bridging required during surgery 
 Requires frequent INR monitoring 
                                                
Close INR 
monitoring 
difficult in 
resource-limited 
settings 
 
 
DOACs 
 
 
 
 
 
 
 Fast onset of action     
 Fixed dosing  
 Fewer drug and food interactions   
 Stable therapeutic levels 
 No regular monitoring required 
 Shorter half-life   
 Predictable pharmacokinetic/ 
pharmacodynamic effects 
 Surgery without bridging 
 Lower ICH risk compared to warfarin    
 Dabigatran dialyzable due to low plasma 
protein binding 
 Prothrombin time can be used to measure 
effect of rivaroxaban 
 Anti-factor Xa can be used to measure effect 
of apixaban                                           
 
 Not indicated for patients with 
valvular AF 
 Twice daily dosing (dabigatran and 
apixaban)     
 Antidotes development in progress      
 Dosage adjustment in renal 
impairment  
 Lack of long term-safety data 
 Gastrointestinal haemorrhage and 
MI risk (dabigatran) 
 Laboratory monitoring tools 
unreliable 
 Cost                                                           
Setting-specific AF 
management 
guidelines and 
further cost-
effectiveness 
studies required  
AF: atrial fibrillation; ICH: intracranial haemorrhage; INR: international normalised ratio; MI: myocardial 
infarction; DOACs: non-VKA-oral anticoagulants 
 
 
1.8.1 Safety and efficacy issues 
There are a range of safety and efficacy issues particularly relevant to prescribers when 
considering the place of DOACs in stroke prophylaxis in AF. The safety data generated by 
clinical trials is not enough to provide recommendations regarding the place of DOACs in 
real-world practice, or to suggest that they should replace warfarin therapy. However, given 
that warfarin therapy is sometimes poorly controlled, DOACs could have a wider safety 
margin as compared to warfarin. Hence, DOACs could potentially be assessed as an 
alternative to warfarin therapy taking into account safety, efficacy and cost-effectiveness 
issues prior to their introduction. 
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1.8.2 Ethnicity 
It is recognised that ethnicity can influence the pathophysiology of disease, and therefore 
patient response to therapy.(135) A sub-analysis of RE-LY (136) conducted to identify the 
effects of dabigatran versus warfarin on ischaemic and haemorrhagic strokes and bleeding in 
Asian and non-Asian patients revealed haemorrhagic stroke rates were higher with warfarin 
in Asians versus non-Asians, despite similar blood pressure, younger age, and lower INR 
values. Haemorrhagic strokes were significantly reduced with dabigatran in both Asians and 
non-Asians. The benefits of dabigatran were consistent across Asian and non-Asian 
subgroups. These data are particularly reassuring for prescribers in Asian developing 
countries. 
 
1.8.3 Short half-life 
The short half-life of these drugs could make patients more prone to stroke or SE if doses are 
missed and not taken regularly. The short half-life of these drugs, along with the lack of 
routine coagulation monitoring measures and approved algorithms for the same, makes it 
difficult to ascertain with the DOACs if therapeutic failure is due to clinical causes (drug-
drug interactions etc.) or patient nonadherence. Comprehensive patient counselling will play 
an important role in prevention and self-reporting of these adverse outcomes.   
 
1.8.4 No routine coagulation monitoring required 
The lack of a readily available assay to precisely measure the anticoagulation effect of the 
DOACs may be problematic. This is especially true in emergency situations, but also during 
chronic therapy. The short half-life of the DOACs makes strict adherence to therapy vital; 
patients are more prone to stroke or SE if doses are missed and not taken regularly. Unlike 
with warfarin, where regular INR monitoring provides objective evidence for assessing non-
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adherence and the risk of thrombosis or bleeding-related outcomes, the lack of such regular 
monitoring with DOACs can potentially increase the risk of stroke or SE due to undetected 
poor drug adherence.  
 
 Furthermore, it has been observed that there is large variability in the plasma 
concentrations achieved with any given dose of dabigatran, depending on absorption, renal 
function, and other patient factors.(63, 137, 138) Variation in plasma concentration could 
potentially lead to under-response or over-response to dabigatran. This may hold true for 
other DOACs as well. A range of commercial assays, like the anti-Xa and chromogenic 
assays are in development but have not yet been approved. Measures like prothrombin time, 
thrombin time, activated partial thromboplastin time, ecarin clotting time, prothrombinase-
induced clotting time, and modified prothrombin time are being used with varying degrees of 
success.(139-144) The monitoring limitations of the DOACs further emphasise the 
importance of the appropriate choice of drug and dose based on patient characteristics in an 
attempt to ensure optimal therapeutic benefits. Lack of monitoring tools can also be 
problematic in patients having comorbid conditions, such as renal disease, where dosage 
adjustments are required to optimise safety.  
 
1.8.5 Reversal agents  
Clinical trials have shown the bleeding profiles of DOACs, particularly ICH and 
haemorrhagic stroke, are better than that of warfarin. Furthermore, a recent review of five 
phase III trials comparing dabigatran with warfarin showed patients experiencing major 
bleeding on dabigatran required less intensive monitoring and had a lower mortality rate than 
those taking warfarin.(145) Nevertheless, specific guidelines are required for managing 
DOAC-related bleeding. Currently, the management of bleeding due to DOACs is based on 
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experts’ opinions or laboratory endpoints, rather than on clinical experience.(146) 
Monoclonal antibodies against the DOACs and recombinant Xa-analog to reverse the factor 
Xa inhibitors are being investigated in clinical trials.(147) A humanised Fab fragment of a 
monoclonal antibody against dabigatran appears to give rapid and complete inhibition of its 
anticoagulant effect.(148)  
 
 Idarucizumab is the first dabigatran-specific antidote. It is a humanised monoclonal 
antibody that binds specifically to dabigatran and has an affinity 350 times greater than 
thrombin.(149, 150) The REVERSAL Effects of Idarucizumab in Patients on Active 
Dabigatran (RE-VERSE AD) study is an ongoing phase III trial, evaluating the reversal of 
the anticoagulant effects of dabigatran in patients who present with uncontrollable or life 
threatening bleeding or require emergency surgery or procedures.(150) The results of this 
trial found that idarucizumab completely reversed the anticoagulant effect of dabigatran in 88 
to 98% of patients within minutes. The dabigatran associated anticoagulant reversal action of 
idarucizumab is shown in Figure 1.4A and 1.4B.(151)  
 
 Andexanet alfa is another antidote, currently studied to evaluate its safety and 
efficacy in reversing apixaban and rivaroxaban-induced anticoagulation in healthy volunteers 
in two parallel trials - Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of 
FXA Inhibitors Apixaban (ANNEXA-A) and Rivaroxaban (ANNEXA-R).(152) The trials 
concluded that andexanet can reverse the anticoagulant activity of apixaban and rivaroxaban 
in older healthy participants within minutes after administration and for the duration of 
infusion, without evidence of clinical toxic effects. 
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A 
 
dabigatran bound thrombin is unable to participate in clotting function 
B 
 
 
                 Excreted in urine                      Returns to clotting activity 
Figure 1.4A: dabigatran (D) thins the blood by binding to a specific clotting factor, thrombin (T), and 
preventing it from functioning normally. This lack of thrombin function thins the blood. 
Figure 1.4B: idarucizumab (IDA) reverses the anticoagulation effect of dabigatran by binding to dabigatran 
with >350 times the strength with which dabigatran binds to thrombin (T). This leaves thrombin free to once 
again participate in the clotting process. The IDA-D complex then leaves the body in the urine. 
 
1.8.6 Gastrointestinal bleeding 
A recent meta-analysis (153) of 43 randomised controlled trials (151,578 patients) that 
compared DOACs with standard care has confirmed a 40-50% increase in the risk of GI 
bleeding associated with DOACs. The study defined standard care as low-molecular-weight 
heparin, VKA, antiplatelet therapy, or no (additional) therapy/placebo, depending on the 
guidelines regarding antithrombotic therapy for the relevant indication. Among the drugs 
studied, the OR values were: apixaban 1.23 (95% CI, 0.56-2.73), dabigatran 1.58 (95% CI, 
1.29-1.93), edoxaban 0.31 (95% CI, 0.01-7.69) and rivaroxaban 1.48 (95% CI, 1.21-1.82). 
This highlights the importance of risk stratifying patients to identify individuals at increased 
risk of DOAC-related GI bleeding.  
 
Using bleeding assessment tools like the HAS-BLED score (33) may help to identify 
patients at increased risk of GI bleeding before prescribing any anticoagulant therapy. This 
risk score was used to investigate predictors of bleeding in a cohort of patients with AF 
participating in the SPORTIF (Stroke Prevention using an Oral Thrombin Inhibitor in atrial 
D T 
IDA D T 
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Fibrillation) III and V clinical trials.(35, 154-156) These trials included patients from 
different countries in Europe, Asia, and Australasia, suggesting the utility of this tool in 
developing, as well as in developed, countries. The analysis predicted diabetes and heart 
failure or left ventricular dysfunction as additional risk factors for bleeding.  
 
1.8.7 Dose adjustments in chronic kidney disease (CKD) 
As warfarin is not renally excreted, it can generally be used in patients with a creatinine 
clearance (CrCl) less than 30mL/min. Use of DOACs in renally impaired patients requires 
very close monitoring of the renal status of the patients to prevent overdose-associated 
toxicities with these drugs. Dose adjustments are recommended as renal function declines, 
and DOACs are contraindicated in stage 4 and stage 5 CKD as sufficient data on the use of 
DOACs in these patients are lacking.(157)  
 
1.8.8 Switching between different anticoagulants 
Proper evidence-based guidelines need to be formulated for effective antithrombotic therapy 
in patients with AF. Currently, switch-over practices between different antithrombotic drugs 
should be based on international guideline recommendations. Physicians should be familiar 
with basic pharmacological and pharmacokinetic properties of OACs to keep the switch-over 
practices safe (158), and ensure adequate crossover of agents and bridging when 
necessary.(158) 
 
 Switching from warfarin is advocated only if INR control has been poor or if 
frequent monitoring is problematic.(59) The findings of a recent study also suggest that 
caution should be adopted when shifting high-risk patients from VKA to dabigatran 
treatment.(98) The SAMe-TT2R2 score [sex (female), age (<60 years), medical history 
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(defined as more than two of the following: hypertension, diabetes, coronary artery 
disease/myocardial infarction, peripheral arterial disease, congestive heart failure, previous 
stroke, pulmonary disease, and hepatic or renal disease), treatment (interacting drugs, e.g., 
amiodarone for rhythm control), tobacco use (within 2 years), race (non-white)] (Table 1.12) 
aids decision-making for physicians by identifying patients with AF who are likely to do well 
on warfarin (score 0-1) or those who are more likely to have poor anticoagulation control 
(score >2).(159) Patients with a score greater than 2 could benefit from DOACs as initial 
therapy or alternatively be identified for use of more aggressive interventions for better 
anticoagulation control.(160) This could be a very useful tool to attempt to rationalise the use 
of DOACs, and ensure their receipt by those patients likely to obtain the most benefit from 
them.  
 
Table 1.12 Definition of the SAMe-TT2R2 score 
Acronym Definitions Point 
S Sex (female) 1 
A Age (<60 years) 1 
Me Medical history 1 
T Treatment (interacting drugs e.g., amiodarone for rhythm 
control)  
1 
T Tobacco use (within 2 years) 2 
R Race (non-Caucasian) 2 
 Maximum points 8 
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1.8.9 Drug-drug interactions  
Although DOACs have a much lower potential for drug-drug interactions (DDIs) than warfarin, 
they are not without risk. As with all OACs, concomitant use of other anticoagulants, platelet 
inhibitors or NSAIDs increases the risk of bleeding.(146) In addition, physicians need to 
consider the pharmacokinetic effects of accompanying drugs when prescribing DOACs.(146) 
Clinically relevant DDIs are known to result as dabigatran, rivaroxaban, and apixaban are 
substrates of P-glycoprotein (P-gp) and rivaroxaban and apixaban are metabolized by 
cytochrome P450 3A4 (CYP3A4).(161-163) Drugs that are administered concurrently to AF 
patients may have relevant activity against P-gp and/or CYP3A4, and thus may result in DDIs 
with DOACs. While prescribers may be familiar with the pharmacokinetic DDIs of warfarin, 
there may be relatively unfamiliarity with the DDIs of DOACs. Hence, clinicians should be 
aware of the relevant potential interactions with the P-gp and cytochrome P450 systems.(70, 
157) Caution, possibly with a dose reduction for some of the DOACs, is recommended in 
patients on concomitant therapy with a strong P-gp inhibitor (e.g. amiodarone, verapamil and 
ketoconazole); while potent inducers such as rifampicin, carbamazepine or phenytoin may result 
in therapeutic failure and should not be administered concomitantly.  
 
1.8.10 DOACs in patients with mechanical heart valves 
The use of dabigatran in patients with mechanical heart valves has been associated with 
increased rates of TE and bleeding complications compared to warfarin (164-166), perhaps due 
to inadequate plasma dabigatran concentrations.(167, 168) Hence, the direct thrombin inhibitor 
dabigatran is contraindicated in patients with AF and a mechanical heart valve.(169) Information 
on safety and efficacy of other DOACs is lacking in this condition; guidelines suggest avoiding 
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other DOACs until more data is available.(6) Lack of usefulness of DOACs in this condition 
suggests the need for specific thromboprophylaxis guidelines, mindful of the needs of these 
patients.  
  
1.8.11 Risk of MI   
There exist significant differences in the comparative safety of apixaban, rivaroxaban and 
dabigatran with regards to acute coronary adverse events.(170) In the RE-LY study, dabigatran 
was associated with a significantly higher MI rate than warfarin (RR: 1.38 for dabigatran 150mg, 
P=0.048; RR: 1.35 for dabigatran 110mg, P=0.07).(66) A recent meta-analysis of randomized 
controlled trials investigating the risk of MI with the use of DOACs also suggested that they 
were associated with an increased risk of MI.(171) Overall, there is a lack of conclusive evidence 
to support the association between DOACs and MI, although some of the initial signals are of 
concern.(171) Prospective evaluation of the DOACs is expected to provide more convincing data 
regarding outcomes in real world practice. 
 
1.8.12 Cost-effectiveness  
Emerging evidence suggests that the new anticoagulants are cost-effective across a range of 
health settings with incremental cost-effectiveness ratios (ICERs) against warfarin ranging from 
$3,547 to $150,000 in different health care settings.(172) A recent review (173) concluded that 
the economic and clinical benefits of the DOACs, along with appropriate risk stratification, may 
enable a greater proportion of patients with AF to receive effective and convenient prophylaxis. 
In addition, several economic models have shown lowered rates of clinical events, increased 
patient survival and reduced cost of long-term disability with dabigatran therapy.(174-178) The 
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absolute cost of DOACs is significantly higher than the traditional agents, however, and this 
must be taken into account when formulating recommendations to ensure appropriate and 
equitable allocation of limited health care resources.(179) The preferred stroke prevention 
strategy should be carefully determined by the risk of stroke and ICH, quality of warfarin control 
and affordability. Hence, DOACs could be a better option where anticoagulation control with 
warfarin is not optimal. Although warfarin therapy is considered to be relatively inexpensive, the 
costs of frequent laboratory monitoring and of complications due to under-or over-
anticoagulation are considerable.(180) DOACs have the potential to substantially reduce cost 
burden through improved efficacy, safety and ease of use compared with warfarin. Less stringent 
monitoring requirements that remove the burden of care from hospitals and clinics, fewer 
interactions, potential elimination of the need for induction and bridging, reduced education 
intensity and a more stable and consistent level of anticoagulation could minimise the overall 
costs associated with DOACs.(181) A recent review found that, on balance, evidence regarding 
the efficacy and safety of the DOACs suggests that they are a potentially cost-effective 
alternative to warfarin.(182) Nevertheless, the cost of the DOACs both to individuals, and the 
health care system, potentially remains the most significant barrier to patients in developing 
countries switching to DOACs.(183), A study that investigated the cost-effectiveness of five 
alternative AF management strategies (rivaroxaban, warfarin, aspirin plus clopidogrel, aspirin 
and no prevention) in a health-resource-limited setting of China concluded that although 
rivaroxaban can improve health outcomes compared with warfarin and antiplatelet-based 
strategies, it was not cost-effective at its current price.(179) The authors stated that, in resource-
limited settings, a more pragmatic approach was to increase warfarin utilisation and, in 
particular, improve the quality of INR control.(179) Further studies comparing the cost-
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effectiveness of DOACs and other strategies are required in other developing regions. An 
additional consideration is that the willingness to pay (WTP) per quality-adjusted life year 
(QALY) value is low in developing countries.(184, 185) Hence, the advantages of DOACs 
discussed so far may be outweighed by this lower WTP/QALY, resulting in warfarin being 
favoured in developing countries. It is thus evident that optimal prescribing of DOACs warrants 
the development of a model that takes into account budget assessment, communication programs 
with all key stakeholders, patient follow-up and  adherence evaluation by authorities to better 
manage the entry of these agents into practice and to avoid their premature withdrawal and/or 
struggle for funding.(186) This principle unequivocally applies to resource-limited settings as an 
aid for their decision-making process in relation to DOACs. 
 
The alternative approaches to improve  existing anticoagulation therapy in resource 
limited settings include the use of point-of-care (POC) testing, warfarin-dosing-protocols, 
anticoagulation management services with dedicated personnel (i.e., anticoagulation clinics) and 
computer software programs to aid in dose adjustments.(187) Anticoagulation managed by 
anticoagulation clinics was found to give better outcomes and to be a cost-effective alternative 
compared to patients’ managed by their personal physicians in China.(188) Similarly, POC 
measurement offers the potential for both simplifying and improving oral anticoagulation 
management in the professional setting as well as at home and has proven to be an effective 
monitoring modality.(187, 189-191) There is the potential that similar benefits could be observed 
in resource limited countries, especially in settings with poor access to pathology services.(189) 
Further research to assess the relative cost-effectiveness of these strategies compared to 
introduction of the DOACs would better inform appropriate allocation of health resources.  
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1.9 DOACs into clinical practice 
DOACs have been approved for use in Australia and are widely available in the developed 
world. In countries where these drugs have not yet been introduced, prior to the introduction of 
DOACs, however, a model must be developed to aid in the decision-making process regarding 
the launch of these agents in a particular country. Making decisions that take cost-effectiveness 
of healthcare interventions into account, in addition to safety and efficacy, has become a genuine 
concern. Hence, the evaluation of the introduction of new drugs should consider safety, budget 
concerns and the quality of oral anticoagulation care achieved by each country. The choice 
between the available DOACs should be based on patient preferences, adherence, and ease of 
administration, as well as on local factors affecting cost-effectiveness.(192) Country-specific 
guidelines must be developed for the management of AF to aid clinicians in choosing the right 
NOAC for the right patient and at the right dose, and in performing the necessary follow-up and 
monitoring. VKAs may continue to have a role in selected patients or countries, especially if 
alternative monitoring strategies can be utilised. Ideally, prospective registries should be 
established in every country where feasible to investigate the comparative safety, efficacy and 
cost-effectiveness of DOACs and VKAs, to better define the roles of these agents into the future. 
 
1.10 Rationale for the Tasmanian AF (TAF) study  
Although antithrombotic therapy is essential for stroke prevention in AF, there is limited data on 
the pattern of use of these drugs in the Tasmanian population. The available literature suggested 
that there was underutilisation of anticoagulant therapy (193, 194), although this data come from 
relatively small observational trials in selected patient groups.(193, 195) The Commonwealth 
Review of Anticoagulation Therapies in AF in Australia identified that stroke prevention in 
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individuals with AF requires improvement, and highlighted a range of issues to be addressed 
related to the assessment of patients for stroke and bleeding risk, appropriate choice of 
antithrombotic agent(s) in patients with multiple comorbidities, and the monitoring of 
patients.(53) The review stressed the need for local data on which to base recommendations 
regarding the treatment of AF. Additionally, since there was also a lack of a contemporary, 
comprehensive Australian guideline for the management of AF to assist in decision-making 
process and to optimise outcomes, the review highlighted the need of national AF management 
guidelines. Meanwhile, little was known about the clinical outcomes and safety of DOACs 
outside the trial setting. In 2011, dabigatran’s sponsor launched patient familiarisation program 
in which over 28,000 Australians were enrolled. Thus, the need of critical local data regarding 
the safety of antithrombotic medications, including the DOACs, in the treatment of AF and a 
comprehensive national guideline for the detection and management of AF was deemed 
necessary in Australia. This study aimed to contribute to the development of national guidelines 
for AF management in Australia with its explicit focus on rational use of antithrombotic therapy. 
The rationale behind this project was to derive local data on usage patterns of antithrombotic 
therapy, clinical outcomes and their safety profile in Australian sub-population prior to the 
Pharmaceutical Benefits Scheme (PBS) listing of DOACs and establish an ongoing study to 
monitor the prescribing and outcomes of stroke prevention in AF in a cohort of Australian 
patients. 
 
 We designed this study, the TAF Study, as a starting point to providing comprehensive 
data describing the outcomes of current stroke prevention strategies in Tasmanian patients with 
AF. The TAF study is an ongoing retrospective study that enrols patients from three different 
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hospitals in Tasmania, Australia; the Royal Hobart Hospital (RHH), Launceston General 
Hospital (LGH) and North West Regional Hospital (NWRH).  
 
1.11 Aims and objectives 
The main aims of this study were to retrospectively:  
1) Review the patient characteristics and antithrombotic treatment patterns among patients with 
AF in Tasmanian hospitals, 
2) Compare the anticoagulant utilisation to earlier data in the same population and identify 
predictors of anticoagulant prescribing among patients with NVAF, 
3) Evaluate the rates of, and factors associated with, hospital readmissions due to bleeding or TE 
complications among patients newly diagnosed with AF, and  
4) Compare the patient characteristics, antithrombotic prescribing patterns, and rates of bleeding 
or TE outcomes between older and younger patients diagnosed with AF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
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Chapter 2:  Patient Characteristics and Antithrombotic Prescribing Patterns 
in Patients with Atrial Fibrillation in Tasmania 
 
2 Abstract  
Limited data are available on AF and its clinical management and outcomes from an Australian 
perspective. This study was designed to examine the patient characteristics and antithrombotic 
treatment patterns among patients with AF in Tasmania, Australia. This retrospective 
observational study reviewed and followed patients with AF admitted to Tasmania’s three major 
hospitals between January 2011 and June 2012. Patients were excluded if they had only one 
episode of AF that reverted spontaneously or upon cardioversion without any documented 
recurrences. We reviewed the records of 2502 patients (≥ 18 years); 1469 were subsequently 
included in the study. The mean ± (SD) age of the patients was 76 ± (12.3) years. The mean (± 
SD) CHADS2 score was 2.1 ± (1.3); 65.7% had a score ≥ 2. In total, only 55.6% of patients with 
CHADS2 score ≥ 2 were receiving anticoagulation and 9.9% were not receiving any 
antithrombotic treatment, whereas 85.4% of those at low risk (score 0) were on antithrombotic 
therapy. Hospitalisation was associated with a significant increase in the rate of combination 
(antiplatelet plus anticoagulant) therapy (P<0.001). Suboptimal use of antithrombotic therapy 
highlights the need to improve AF management in our jurisdiction.  
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2.1 Introduction 
Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder and is increasing 
in incidence and prevalence in aging populations.(1) Studies indicate that 1.5-2% of the 
developed world population suffers from AF.(8) AF often coexists with hypertension (HTN), 
heart failure, coronary artery disease, and diabetes mellitus, (196) and increases the risk of 
mortality and morbidity, particularly due to stroke or thromboembolism (TE).(11)  
 
 Studies have provided details of the characteristics, risk profiles, management, and 
clinical outcomes of patients with AF.(103, 197) Although all contemporary guidelines 
recommend prophylaxis with antithrombotic agents in people with AF and at least one other risk 
factor for stroke, (7, 16) there have been consistent reports of underuse of anticoagulation, as 
well as overuse in low risk patients.(103, 198) For instance, the EURObservational Research 
Programme on Atrial Fibrillation (EORP-AF) Pilot Survey revealed that antiplatelet therapy was 
still being overprescribed, with or without anticoagulation, while elderly patients were 
commonly undertreated with oral anticoagulation despite their high risk of stroke and 
thromboembolic complications.(197)  
 
At present there are limited data available on the characteristics, clinical management and 
outcomes of patients with AF from an Australian perspective. The available literature suggests 
that there is underutilisation of anticoagulant therapy, (193, 194) although this data comes from 
relatively small observational trials in selected patient groups.(193, 195) The Commonwealth 
Review of Anticoagulation Therapies in AF in Australia identified that stroke prevention in 
individuals with AF requires improvement, and highlighted a range of issues to be addressed 
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related to the assessment of patients for stroke and bleeding risk, appropriate choice of 
antithrombotic agent(s) in patients with multiple comorbidities, and the monitoring of 
patients.(53) The review stressed the need for local data on which to base recommendations 
regarding the treatment of AF. We designed this study, the Tasmanian AF (TAF) Study, as a 
starting point to providing comprehensive data describing the outcomes of current stroke 
prevention strategies in Tasmanian patients with AF. The aim of the current paper is to describe 
the characteristics of patients with AF admitted to three different Tasmanian hospitals and the 
appropriateness of antithrombotic prescribing patterns according to existing guideline 
recommendations.  
 
2.2 Materials and Methods 
2.2.1 Study design 
Patients were identified by the Medical Record Departments at the Royal Hobart Hospital 
(RHH), Launceston General Hospital (LGH) and North West Regional Hospital (NWRH). The 
RHH is a 500-bed hospital servicing the southern region of Tasmania, Australia (population of 
255,614). The LGH is a 300-bed hospital servicing residents of Launceston and the northern 
region of Tasmania (population of 143,544). Similarly, the NWRH is a 160-bed hospital 
providing services to North West Tasmania and King Island (population of 114,001).(199) 
 
We reviewed medical records (admissions between 1
st
 January 2011 and 30
th
 June 2012) 
of 2502 patients aged ≥ 18 years with a diagnosis of AF (both valvular and non-valvular) at 
discharge (Australian Refined Diagnosis Related Group (AR-DRG) code I48: atrial fibrillation 
or flutter). Patients diagnosed with AF as their primary (i.e. AF was the presenting complaint) or 
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secondary condition (i.e. AF was listed as a current illness in the medical history or discharge 
summary) were included. Patients were excluded if they had only one episode of AF that 
reverted spontaneously or upon cardioversion without any documented recurrences, as stroke 
prophylaxis may not be warranted in these patients. Contraindications (CIs) to anticoagulant 
therapy included a history of dementia, documented labile INR, bleeding disorders, or allergies 
to anticoagulant therapy, and breastfeeding or pregnancy in women. We considered a patient’s 
index admission as their first admission within our data collection period with a diagnosis of AF 
that met the study’s inclusion criteria.  
 
Data collected at baseline (i.e. at each patient’s index admission) included patient 
demographics, medications on admission, documented previous medical history, relevant 
laboratory data, discharge diagnosis and discharge medications. The CHADS2 and CHA2DS2-
VASc risk assessment scores were used to estimate stroke risk. The CHADS2 score was derived 
by allocating one point each for CHF, HTN, age ≥75 years and diabetes, and two points for 
previous stroke or TIA.(17) The CHA2DS2-VASc score was calculated by assigning one point 
each to CHF, HTN, diabetes, vascular disease (prior MI, peripheral artery disease or aortic 
plaque), age 65-74 years and female gender, and two points for age ≥75 years and previous 
stroke or TIA or TE.(20) A CHADS2 score of 0 was considered low risk, 1 intermediate risk and 
≥2 high risk; while a CHA2DS2-VASc score of 0 represented low risk and ≥1 was considered 
intermediate-high risk. The HAS-BLED score was used to estimate bleeding risk assessment. It 
was derived by allocating one point each for HTN, abnormal renal function, abnormal liver 
function, bleeding pre-disposition, age >65  years, labile INRs (if documented), the use of drugs 
predisposing patients to bleeding (NSAIDs), alcohol use (>8 drinks per week) and previous 
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stroke.(33) A HAS-BLED score of 0 indicated low risk, 1-2 indicated intermediate risk and ≥ 3 
indicated high risk. Even though the CHA2DS2-VASc and HAS-BLED scores were not available 
to clinicians to guide treatment during the study time period, they were included in the analysis 
to assist in interpretation of our results. The Charlson Comorbidity Index (CCI) was used as a 
measure of comorbidity.(200)  
 
Our ‘antiplatelet’ group consisted of patients receiving aspirin, clopidogrel, prasugrel, 
dipyridamole or ticagrelor either alone or in combination with each other but not in combination 
with an anticoagulant. The ‘lone anticoagulant’ group consisted of cases receiving warfarin, 
dabigatran, heparin, fondaparinux or enoxaparin. Patients taking a combination of an 
anticoagulant with an antiplatelet agent constituted the ‘combination therapy’ group. Finally, 
patients receiving any one of these drug groups were considered to be on antithrombotic therapy 
i.e. either on antiplatelet or anticoagulant or on combination therapy. We utilised the 
recommendations from the European Society of Cardiology (ESC) 2010 guidelines and 
American College of Chest Physicians (ACCP) 9
th
 edition, (7, 16) to examine the 
appropriateness of antithrombotic prescribing at discharge of the index admission. We 
considered underutilisation as non-prescribing of anticoagulation, with or without antiplatelet 
therapy, to patients without documented CIs to anticoagulant therapy and a CHADS2 score ≥ 2 as 
per these guidelines.  
 
2.2.2 Statistical analysis 
Data were analysed using SPSS version 21 (Prentice Hall, USA). Continuous variables were 
expressed as mean ± standard deviation (SD). Categorical variables were expressed as 
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frequencies and percentages. Differences between cohorts were tested for statistical significance 
using Mann-Whitney U and Chi-square tests, as appropriate. P<0.05 was considered as 
statistically significant for all analyses. 
 
 Ethics approval for the project was obtained from Tasmanian Health and Medical Human 
Research Ethics Committee. 
 
2.3 Results 
2.3.1 Baseline characteristics  
The medical records of 2502 patients were reviewed, of whom 1469 were included (RHH: 777, 
NWRH: 289, LGH: 403) and 1033 were excluded (episode of AF that reverted spontaneously or 
upon cardioversion: 590, developed AF as a short-term complication: 288, no documented AF 
[coding error]: 155). The mean ± (SD) age of the included patients was 76 ± (12.3) years; 55.6% 
were male. Valvular AF was observed in 11.3% (166) of patients. HTN was the most commonly 
associated comorbid condition (65.7%). The demographics and clinical characteristics of the 
patients are summarised in Table 2.1.  
 
 The mean ± (SD) CHADS2 score was 2.1 ± (1.3), and 65.7% had a score ≥2. The mean ± 
(SD) CHA2DS2-VASc score was 3.7 ± (1.7); 8.2% had a score of 1, while 88.6% had a score ≥2. 
The majority of the patients (73.5%) had an intermediate HAS-BLED score of 1-2, as shown in 
Table 1. A CI to antithrombotic treatment was documented in 9.9% of patients. 
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 Table 2.1 Baseline characteristics of patients enrolled in TAF study 
Variables All patients (n=1469) 
Age in years, Mean (SD) 76.0 (±12.3)   
Age group, n (%)  
≥65  1249 (85.0) 
≥75  878 (59.7) 
≥80  628 (42.7) 
≥85 325 (22.1) 
Men, n (%) 817 (55.6) 
Medical history, n (%)   
Hypertension 965 (65.7) 
Ischaemic heart disease  509 (34.6) 
Congestive heart failure  377 (25.7) 
Chronic respiratory disease 374 (25.5) 
Diabetes 310 (21.1) 
Cerebrovascular disease 295 (20.1) 
Myocardial infarction  238 (16.2) 
Embolic events (DVT, Pulmonary embolism) 109 (7.4) 
Peripheral vascular disease 90 (6.1) 
History of bleeding  37 (2.5) 
Valvular heart disease, n (%) 166 (11.3) 
AF history, n (%)  
     First detected AF 387 (26.3) 
     Previous AF  1082 (73.6) 
CCI (classic), Mean (SD) 5.3 (±2.4) 
CHADS2, Mean (SD) 2.1 (±1.3) 
Low (score 0) 153 (10.4) 
Intermediate (score 1) 350 (23.8) 
High (score 2-6) 966 (65.7) 
CHA2DS2-VASc, Mean (SD) 3.7 (±1.7) 
Low (score 0) 45 (3.1) 
Intermediate (score1) 121 (8.2) 
High (score 2-9) 1303 (88.6) 
HAS-BLED, Mean (SD) 1.8 (±0.8) 
Low (score 0) 93 (6.3) 
Intermediate (score1-2) 1079 (73.5) 
High (score ≥3) 297 (20.2) 
Antithrombotic therapy (on admission), n (%)  
Antiplatelet therapy  578 (39.3) 
Anticoagulant therapy  463 (31.5) 
AP/AC combination 101 (6.8) 
No antithrombotic therapy 327 (22.2) 
Other medications, n (%)  
PPIs  
H2Bs  
Statins  
Prednisolone 
NSAIDs 
551 ( 37.5) 
40 (2.7) 
661 (45.0) 
149 (10.1) 
83 (5.7) 
Reason for index admission, n (%)  
Related to AF 390 (26.5) 
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Variables All patients (n=1469) 
Bleeding 63 (4.3) 
Thromboembolism 189 (12.9) 
Other cardiovascular conditions 
None of the above 
258 (17.6) 
569 (38.7) 
AP/AC: antiplatelet and anticoagulant; AF, atrial fibrillation; CCI, Charlson comorbidity index; DVT, deep vein 
thrombosis; H2Bs, histamine-2 receptor blockers; PPIs, proton pump inhibitors; NSAIDs, non-steroidal anti-
inflammatory drugs; SD, standard deviation. 
 
 
2.3.2 Thromboprophylactic treatment  
Based on ACCP 9
th
 edition and ESC 2010 guidelines, (7, 16) 64.1% (n=808) of the 1261 patients 
with no documented CIs to antithrombotic therapy had a CHADS2 score ≥ 2 and were therefore 
eligible for anticoagulant therapy (Table 2.2). An anticoagulant was prescribed for 55.6% 
(n=449) of these patients at discharge. These percentages were broadly similar for the 
intermediate risk (CHADS2=1) group. Antiplatelet agents were prescribed in an additional 34.5% 
(n=279) of patients. Eighty (9.9%) patients with a CHADS2 score ≥ 2 were not receiving any 
antithrombotic therapy. “Physician decision” was the only documented reason for not prescribing 
antithrombotic therapy (n=34, 3.0%), despite patients having intermediate to high risk of stroke 
(CHADS2 score ≥1) without any CIs. In contrast, 85.4% (n=123/144) of patients in whom no 
treatment may have been indicated due to their low risk of stroke (CHADS2=0) were receiving 
antithrombotic therapy. Only 5.6% (n=8/144) of these patients had an embolic disease history 
other than AF and therefore alternative indications for anticoagulation. Furthermore, among 
those receiving lone antiplatelet agents and having a CHADS2=0, 16.3% (8/49) had a history of 
ischaemic heart disease (IHD).  
 
Similar findings arose when prescribing was evaluated against patients’ CHA2DS2-VASc 
scores. In this case, 96.9% (n=1222/1261) of patients with no CIs to antithrombotic therapy had 
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at least one additional risk factor for stroke and were therefore eligible for anticoagulant therapy 
(Table 2.2). An anticoagulant was prescribed for 57.0% (n=697/1222) of these patients. 
Antiplatelet agents were prescribed in 33.1% (n=405).  
 
In assessing if anticoagulant underuse was associated with a high HAS-BLED score, we 
observed that 22.0% (n=278/1261) of patients without any CIs had a HAS-BLED score which 
exceeded their CHADS2 score. Of these patients, 56.5% were on anticoagulant therapy, 34.9% 
on antiplatelet therapy, and 8.6% receiving no therapy, which was largely consistent with the 
overall population.  
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 Table 2.2 Use of antithrombotic therapies, overall and according to CHADS2 and CHA2DS2-VASc scores on discharge (excludes those with contraindications 
and those for whom no information was available, n =1261) 
CHADS2 scores 
Antiplatelet therapy 
(%)
a
 
Anticoagulant 
therapy (%)
b
 
Combination therapy 
(%)
c
 
Any Antithrombotics (%)d No therapy (%) 
CHADS2 =0 (n=144) 49 (34.0) 56 (38.9) 18 (12.5) 123 (85.4) 21 (14.6) 
CHADS2 =1 (n=309) 90 (29.1) 130 (42.1) 61 (19.7) 281 (90.9) 28 (9.1) 
CHADS2 ≥ 2 (n=808) 279 (34.5) 307 (38.0) 142 (17.6) 728 (90.0) 80 (9.9) 
Total (n=1261) 418 (33.1) 493 (39.1) 221 (17.5) 1132  (89.8) 129 (10.2) 
CHA2DS2-VASc scores 
Antiplatelet therapy 
(%)a 
Anticoagulant 
therapy (%)b 
Combination therapy 
(%)c 
Any Antithrombotics (%)d No therapy (%) 
CHA2DS2-VASc =0 (n=39) 13 (33.3) 14 (35.9) 3 (7.7) 30 (76.9) 9 (23.1) 
CHA2DS2-VASc ≥1 (n=1222) 405 (33.1) 479 (39.2) 218 (17.8) 1102 (90.2) 120 (9.8) 
Total (n=1261) 418 (33.1) 493 (39.1) 221 (17.5) 1132 (89.8) 129 (10.2) 
a The antiplatelet only group consisted of cases receiving aspirin, clopidogrel, prasugrel, dipyridamole, ticagrelor either alone or in combination with 
each other but not in combination with anticoagulants. 
b The anticoagulant group consisted of cases receiving warfarin, dabigatran, heparin, fondaparinux and enoxaparin.  
c The combination of an anticoagulant with an antiplatelet constituted the combination therapy group.  
d Total antithrombotic therapy in each category
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Of the patients without CIs, 11.4% (144/1261) had valvular AF. Among these patients, 
54.9% were prescribed lone anticoagulant therapy, followed by combination therapy (23.6%), 
and 15.3% were taking antiplatelet monotherapy. The prescribing pattern of antithrombotic 
therapy differed significantly between the patients with valvular and nonvalvular AF, with higher 
rates of prescribing of lone anticoagulant therapy (54.9% vs. 37.1%, P<0.001) and combination 
therapy (23.6% vs. 16.7%, P<0.001), and a correspondingly lower rate of lone antiplatelet 
therapy (15.3% vs. 35.6%, P<0.001).  
 
We also observed a significant difference in the prescribing pattern of combination 
antithrombotic regimens between the patients who were newly initiated (i.e. started 
antithrombotic therapy during the index admission) and continuing therapy (i.e. those on 
antithrombotic treatment prior to their index admission). A larger proportion of newly initiated 
patients were prescribed combination antithrombotic therapy (25.8% vs. 18.0% for the 
continuing group; P<0.001). Recent diagnosis of acute coronary syndrome (ACS), as a potential 
indication for combination therapy, did not seem to have increased its prescribing between these 
groups, with 4.0% of those newly initiated and 4.5% of those continuing on antithrombotic 
therapy diagnosed with ACS during their index admission (P=0.71). 
 
2.3.3 Impact of hospitalisation on antithrombotic prescribing 
When the antithrombotic prescribing patterns on admission and discharge were compared among 
the 693 patients who had a pre-existing AF continuing on antithrombotic treatment, significant 
changes were observed, with a reduction in the prescribing of lone antiplatelet (40.8% vs. 33.5%, 
P<0.001) and anticoagulant therapy (49.2% vs. 47.5%, P<0.001), and an increased rate of use of 
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combination therapy (10.0% vs. 18.9%, P<0.001) (Table 2.3). Only 4.0% of those with pre-
existing AF continuing on antithrombotic therapy were diagnosed with ACS during their index 
admission. 
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Table 2.3 Antithrombotic therapy change associated with hospitalisation (only patients with pre-existing AF continuing on ATT, n=693) 
 
a The antiplatelet only group consisted of cases receiving aspirin, clopidogrel, prasugrel, dipyridamole, ticagrelor either alone or in combination with each other 
but not in combination with anticoagulants. b The anticoagulant group consisted of cases receiving warfarin, dabigatran, heparin, fondaparinux and enoxaparin. 
c The combinations of an anticoagulant with an antiplatelet constituted the combination therapy group. Therapy changes: Antiplatelet: P<0.001*, 
Anticoagulant: P<0.001*, Combination: P<0.001*. 
 
 
 
 
  Admission   Discharge  
CHADS2 score at 
admission 
Antiplatelet
a
 Anticoagulant
b
 Combination
c
 Antiplatelet
a
  Anticoagulant
b
 Combination
c
 
CHADS2 = 0  
(n=60)  
31 
(51.7) 
27 
(45.0) 
2 
(3.3) 
26 
(43.3) 
27 
(45.0) 
7 
(11.7) 
CHADS2 = 1  
(n=170)  
67 
(39.4) 
86 
(50.6) 
17 
(10.0) 
43 
(25.3) 
85 
(50.0) 
42 
(24.7) 
CHADS2 ≥ 2  
(n=463)  
185 
(40.0) 
228 
(49.2) 
50 
(10.8) 
164 
(35.4) 
217 
(46.9) 
82 
(17.7) 
TOTAL (n=693) 283 
(40.8) 
341 
(49.2) 
69 
(10.0) 
232 
(33.5) 
329 
(47.5) 
131 
(18.9) 
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2.4 Discussion 
Observational studies can be valuable in evaluating disease state management and its outcomes 
in a population, especially in countries like Australia which lack effective large-scale healthcare 
data linkage systems. The TAF study, an ongoing observational study of adults with AF, aims to 
comprehensively evaluate the management and outcomes of patients with AF. This paper 
provides a salient snapshot of AF management patterns among patients with AF who 
experienced a hospital admission in three Tasmanian hospitals during 2011 and 2012. In this 
large study of patients with AF we noted that, despite the high risk of stroke and thromboembolic 
complications, anticoagulant therapy was sub-optimal.  
 
 As our patient population was identified during hospital admission, it is perhaps 
unsurprising that they demonstrated high rates of comorbid conditions, especially cardiovascular 
diseases. Nevertheless, their characteristics proved to be largely similar to those of the 
populations studied in the Stockholm AF database, Fushimi AF Registry and ORBIT-AF 
Registry.(105, 107, 201) They were noted to be older and at higher risk of stroke compared to the 
GARFIELD study population, (103) but as GARFIELD is enrolling only patients with new onset 
AF, it is expected that this will have a younger, lower-risk cohort. The retrospective cohort of the 
TAF Study also compares well to the patient cohorts studied in clinical trials comparing NOACs 
to warfarin, in terms of mean age (76 vs. 70-73 years) and stroke risk (mean CHADS2 2.1 vs. 
2.1-3.5).(66, 71, 74, 76) This suggests that our patient population is broadly comparable to that 
of other countries and to those studied in recent pivotal trials, indicating the likely transferability 
of international guidelines and the benefits indicated by these trials’ results to our population.  
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Antiplatelet and anticoagulant therapies are available for stroke prevention in AF. Use of 
anticoagulation therapy for stroke prevention in AF is well accepted, established and 
recommended widely.(3) All contemporary guidelines recommend prophylaxis with 
antithrombotic agents in people with AF and at least one other risk factor for stroke, (7, 16) 
however discordance between AF guideline recommendations and anticoagulant prescribing 
patterns has been reported in various international studies.(103, 202)  
 
In our study, despite the high risk of stroke observed (64.1% of patients had a CHADS2 
≥2, and 96.9% had a CHA2DS2-VASc score of 1 or more), anticoagulant therapy was found to be 
underutilised according to guideline recommendations.(7, 16) At discharge from hospital, almost 
10% of patients with a CHADS2 ≥2 and CHA2DS2VASc score ≥1 were not taking any 
antithrombotic medication and approximately one-third were prescribed antiplatelet 
monotherapy. Given the time frame of our study and the guideline recommendations (16) during 
that time, CHADS2 was the more realistic tool for assessing appropriateness of therapy in 
relation to estimated stroke risk; however, we have presented the results using both CHADS2 and 
CHA2DS2-VASc scores believing that physicians might have also considered the additional risk 
factors subsequently included in CHA2DS2-VASc score.  
 
This underutilisation of anticoagulant therapy in AF patients at relatively high risk of 
stroke is consistent with previous findings, (194, 203) with many clinicians considering the risk 
of anticoagulant treatment to exceed the benefits, when in fact those at higher risk of stroke often 
receive the greatest benefit from anticoagulation.(204) The potential risk of bleeding is one of 
the most frequent reasons of anticoagulant underuse among treating physicians.(205) Since 
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22.0% of our patients without any CIs had a HAS-BLED score which exceeded their CHADS2 
score, this might have contributed to the observed underutilisation of anticoagulant therapy. 
Given that the majority of our patient population were elderly and had multiple comorbidities, 
this might have led to physicians being more reluctant to prescribe anticoagulant therapy. A 
history of anaemia, history of hospitalisation/emergency room visits, older age, comorbidities, 
risk of falls, and previous bleeding have all been identified as reasons for non-prescribing of 
anticoagulants.(46, 103, 133, 206) The belief that antiplatelet therapy alone is sufficient for 
stroke prevention and/or lack of awareness of guideline recommendations (194) may also have 
contributed to the underutilisation of anticoagulant therapy. Nevertheless, the overall use of 
antithrombotic treatment seems to have improved since 1997-1999, when a study conducted 
among 505 patients diagnosed with AF at the RHH found that 24% of patients at high-risk were 
discharged without any antithrombotic therapy.(193)  
 
Over 80% of the patients with a CHADS2 score of 0, who are considered to be ‘low-risk’ 
patients, were receiving antithrombotic drugs at discharge. Nearly 40% of these patients were on 
anticoagulants; this overuse pattern is very similar to that found in the GARFIELD study 
(38.7%).(103) Other indications apart from AF might have justified the use of anticoagulants in 
some of these patients; however, only 5.6% had a history of embolic disease and data regarding 
other possible indications was not collected within the confines of this study. Similarly, a history 
of IHD among those with a CHADS2 score of 0 (16.3%) might have made some patients eligible 
for antiplatelet therapy despite being at a low risk of stroke.  
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The final issue of concern raised by our data was the relatively high rate of prescribing of 
combination anticoagulant/antiplatelet therapy; this rate was especially high in patients newly 
initiated on therapy, and also increased from admission to discharge in patients with existing AF. 
One explanation for this prescribing pattern may be the diagnosis of a compelling guideline-
recommended indication for antiplatelet therapy (e.g. ACS) in patients requiring anticoagulation 
for AF thromboprophylaxis.(16) ACS was only diagnosed among 4.0% of those with old AF 
continuing on antithrombotic therapy during the index admission in our study, however, so this is 
unlikely to have been a major influencing factor. Other potential reasons for the prescribing of a 
combination therapy may have been the use of antiplatelet agents as ‘bridging therapy’ during 
anticoagulant initiation or inappropriate failure to cease antiplatelet therapy upon initiation of 
anticoagulation. This issue warrants further investigation as combination therapy is associated 
with a significantly higher risk of bleeding.(16) 
 
There is clearly an evidence to practice gap in guideline adherence to rational prescribing 
of antithrombotic regimens in patients with AF in our population. Local guidelines and other 
contextual factors may influence anticoagulant prescribing.(194) At present, there are no up-to-
date Australian guidelines for the management of AF; thus, international guidelines are the basis 
of its management, and data regarding predictors of antithrombotic prescribing among patients 
with AF are as yet limited in Australia. The absence of robust national AF management 
guidelines might have influenced underutilisation or overutilisation of anticoagulant therapy in 
our population. Intervention programs, such as described previously, (207, 208) may be required 
to assist with optimising guideline concordance and therefore the proportion of Australian 
patients receiving appropriate thromboprophylaxis for stroke prevention in AF. 
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2.5 Conclusions 
Our study highlights a gap between the evidence-based risk stratification and antithrombotic 
management pattern among patients with AF in Tasmania. In the absence of contemporary local 
guidelines, there appears to be a need to better support prescribers to assist in the identification 
and quantification of patient risk according to accepted international guidelines to optimise 
thromboprophylaxis and reduce the risk of thromboembolic and bleeding complications in this 
vulnerable patient group. 
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Chapter 3: Anticoagulant use in Patients with Non-valvular Atrial 
Fibrillation: has prescribing improved? 
3 Abstract  
Discordance between international guideline recommendations and anticoagulant prescribing 
patterns among patients with non-valvular atrial fibrillation (NVAF) has been frequently 
reported. This study was designed to compare the anticoagulant utilisation pattern to earlier data 
in the same population, and identify predictors of anticoagulant prescribing among patients with 
NVAF. We reviewed patients with NVAF admitted to Tasmania’s three major hospitals between 
January 2011 and June 2012 and compared the anticoagulant utilisation pattern to earlier data. 
Patients were excluded if they had only one episode of NVAF that reverted spontaneously or 
upon cardioversion. Multivariate logistic regression analysis was used to identify predictors of 
anticoagulant prescribing. Overall, 53.8% of patients received anticoagulant treatment compared 
to 40.4% 15 years ago. Among eligible patients at high-risk of stroke, 52.5% were receiving 
anticoagulant therapy (vs. 42.1% 15 years ago). Approximately 10% of patients with a CHADS2 
score ≥2 were not receiving any antithrombotic treatment, reduced from 18.2% in the earlier 
cohort, whereas anticoagulant use increased among those at low risk (score 0) to 48.5% from 
14.2%. Younger age (odds ratio [OR] 0.99, 95% CI 0.97-1.0; P=0.04), CHADS2=1, relative to 0 
(OR 1.68, 95% CI 1.07-2.63; P=0.02), CHF (OR 1.56, 95% CI 1.12-2.15; P=0.008) and embolic 
disease history (OR 1.77, 95% CI 1.09-2.86; P=0.02) were significant predictors of anticoagulant 
prescribing. While there has been improvement over the past 15 years, suboptimal use of 
anticoagulant therapy among high-risk patients with NVAF remains common. There is 
significant potential for improvement in the quality of stroke prophylaxis in patients with NVAF.  
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3.1 Introduction 
Long-term use of anticoagulant therapy is an important strategy in the management of NVAF 
and its efficacy for stroke prevention in this condition is well established.(3) Vitamin K 
antagonists (VKAs) and non-vitamin K antagonist oral anticoagulants (NOACs) can be used for 
thromboprophylaxis. In comparison, antiplatelet therapy has limited utility for preventing stroke 
in AF.(7, 79) Despite the proven benefits of anticoagulant therapy in atrial fibrillation (AF), there 
have been frequent reports of discordance between guideline recommendations and anticoagulant 
prescribing patterns.(103, 202) Early discontinuation and underuse of anticoagulants in real-
world practice have been reported.(46, 103, 133, 206) A retrospective study conducted by 
Jackson et al. 15 years ago (1997-1999) in Tasmania revealed that anticoagulant therapy was 
underused in high-risk patients with AF.(193) This study provided local data on stroke 
prophylaxis measures in AF at a particular point of time and provided the basis for an 
intervention to improve anticoagulant prescribing. In fact, a community-based educational 
intervention carried out among general practitioners, resulted in a significant increase in the 
prescribing of warfarin for stroke prevention in Tasmanian patients with AF.(209) 
 
Contemporary guidelines recommend prophylaxis with antithrombotic agents in people 
with AF and at least one other risk factor for stroke.(7, 16) The guidelines recommend using risk 
stratification schemes, like CHADS2 (17) or CHA2DS2-VASc, (20) to assess the risk of stroke in 
patients with AF prior to commencing antithrombotic treatment. Despite these guidelines, high-
risk of stroke has not been found to be an independent predictor of anticoagulant prescribing in 
several observational studies.(210, 211)  
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Data regarding predictors of anticoagulant prescribing among patients with AF are 
limited in the Australian context. A prospective study conducted across a local health district in 
Sydney (194) revealed that the likelihood of receiving anticoagulant therapy among patients with 
NVAF increased by being classified at high-risk of stroke. Another study, involving a single 
hospital site revealed that patients aged 80 years or more were less likely to be prescribed 
anticoagulation compared to antiplatelet therapy.(207) The need to bridge the gap in translation 
of evidence into clinical practice was deemed necessary in both of these studies. We thus 
designed this study to determine i) the pattern of anticoagulant utilisation, compared with 
guideline recommendations, (7, 16) and predictors of anticoagulant prescribing in patients with 
NVAF and ii) whether stroke prevention in the management of patients with NVAF had 
improved over the past 15 years in Tasmania. 
 
3.2 Materials and Methods 
3.2.1 Study design 
The TAF (Tasmanian Atrial Fibrillation) study is an ongoing retrospective study that enrols patients 
from three different hospitals in Tasmania, Australia; the Royal Hobart Hospital (RHH), 
Launceston General Hospital (LGH) and North West Regional Hospital (NWRH). We identified 
patients from the Medical Record Departments of these hospitals using Australian Diagnosis 
Related Groups (AR-DRGs) codes. Medical records of 2502 patients admitted between 1
st
 
January 2011 and 30
th
 June 2012 and diagnosed with valvular or NVAF at discharge (AR-DRG 
code I48: atrial fibrillation or flutter) were reviewed for this study. Patients diagnosed with AF as 
their primary (i.e. AF was the presenting complaint) or secondary condition (i.e. AF was listed as 
a current illness in the medical history or discharge summary) were included. Patients were 
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excluded if they had only one episode of AF that reverted spontaneously or upon cardioversion 
without any documented recurrences, as stroke prophylaxis may not be warranted in these 
patients. Of 2502 medical records reviewed, 1469 patients were included (RHH: 777, NWRH: 
289, LGH: 403) and 1033 were excluded (episode of AF that reverted spontaneously or upon 
cardioversion: 590, developed AF as a short-term complication: 288, no documented AF [coding 
error]: 155). Seventy-eight (5.3%) index admissions were excluded due to death of the patient or 
unavailability of their records, leaving 1391 patients. Of these, 1261 patients were eligible for 
anticoagulant therapy (i.e. did not possess contraindications (CIs)). After excluding 144 (11.4%) 
patients with valvular AF, 1117 patients with NVAF were included in this analysis.  
 
Data regarding patient demographics, medications on admission, history of comorbid 
conditions and discharge antithrombotic medications were entered into an electronic database. 
The CCI (200) was used as a measure of comorbidity. We evaluated CHADS2 (17) [congestive 
heart failure (CHF), hypertension (HTN), age ≥75 years, diabetes and previous stroke or 
transient ischaemic attack (TIA)], and CHA2DS2-VASc (20) [CHF, HTN, diabetes, vascular 
disease (prior myocardial infarction (MI), peripheral artery disease or aortic plaque), age 65-74 
years, female gender, age ≥75 years and previous stroke or TIA or thromboembolism (TE)] for 
assessing stroke risk and the HAS-BLED (33) [HTN, abnormal renal function, abnormal liver 
function, bleeding pre-disposition, age >65 years, the use of drugs predisposing patients to 
bleeding (NSAIDs), alcohol use (>8 drinks per week), previous stroke and labile INRs (if 
documented)] score for assessing bleeding risk. A HAS-BLED score of 0 indicated low risk, 1-2 
indicated intermediate risk and ≥ 3 indicated high risk. We defined labile INRs as unstable/high 
INRs as recorded in the medical record of our patients. A patient’s first admission to a hospital 
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with the diagnosis of AF within our study period was defined as the index admission. CIs to 
anticoagulant therapy included patients with a documented history of dementia, labile INRs, 
bleeding diseases, allergies to anticoagulant therapy, and pregnancy. 
 
Our definition of anticoagulant therapy for this study comprised anticoagulant therapy, 
with or without concomitant antiplatelet therapy. We utilised the recommendations from the 
European Society of Cardiology (ESC) 2010 guidelines and American College of Chest 
Physicians (ACCP) 9
th
 edition,(7, 16) to examine the appropriateness of anticoagulant 
prescribing at discharge of the index admission. We considered underutilisation as no prescribing 
of anticoagulant therapy to patients without CIs to anticoagulant therapy and a CHADS2 ≥2 as 
per these guidelines. CHA2DS2-VASc scores were not available to clinicians to guide treatment 
during our data collection period. We also compared the changes in anticoagulant prescribing 
patterns referring to a local study conducted by Jackson et al. (1997-1999), 15 years ago in 
Tasmania.(193) This study was a retrospective review of 505 patients with NVAF admitted to 
RHH. The appropriateness of antithrombotic therapy was assessed both on admission and 
discharge from the hospital care, and sufficient data was available to calculate the CHADS2 
scores retrospectively. The study also determined the clinical outcomes (ischaemic stroke, SE or 
bleeding complications with warfarin or aspirin use) in the total population.  
 
3.2.2 Statistical analysis 
Data were analysed using SPSS version 21.0 (Prentice Hall, USA). Continuous variables were 
expressed as median (IQR). Categorical variables were expressed as frequencies and 
percentages. Chi square tests were used to compare categorical variables while Mann-Whitney U 
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tests were used for continuous variables. Multivariate logistic regression modelling was used to 
identify the independent risk factors associated with anticoagulant prescribing in eligible 
patients. Variables which had P≤0.2 in univariate analyses were combined in a multivariate 
logistic regression model (enter method). P<0.05 was considered as statistically significant for all 
analyses. 
 
 Ethics approval for the project was obtained from Tasmanian Health and Medical Human 
Research Ethics Committee. As the study was retrospective prescribing audit, it was not deemed 
necessary to ask for informed consent from the study participants. 
 
3.3 Results 
3.3.1 Clinical characteristics  
The overall rate of anticoagulant use at discharge from the index admission among eligible 
patients was 53.8%. Characteristics of the patients anticoagulated, and not anticoagulated, at 
discharge are shown in Table 3.1. Patients treated with anticoagulants were significantly 
younger, likely to be male, have previously diagnosed AF, and more likely to have CHF and a 
history of embolic events. 
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 Table 3.1: Baseline characteristics of patients with NVAF anticoagulated and not anticoagulated at discharge 
from index admission (n=1117) 
Variable Anticoagulated (n=601) Not anticoagulated (n=516) P value 
Age, years, mean (SD) 74.4 (±12.0)     76.1 (±12.6) 0.002* 
Gender, n (%)    
Male  358 (59.6) 273 (52.9) 0.03* 
Medical history, n (%)    
HTN 404 (67.2) 336 (65.1) 0.46 
CHF 154 (25.6) 96 (18.6) 0.005* 
Diabetes 139 (23.1) 97 (18.8) 0.08 
Cerebrovascular disease 108 (18.0) 100 (19.4) 0.55 
MI 108 (18.0) 79 (15.3) 0.24 
Embolic events (DVT, pulmonary 
embolism etc.) 
55 (9.2) 28 (5.4) 0.02* 
Peripheral vascular disease 41 (6.8) 29 (5.6) 0.41 
CHADS2, median (IQR) 2.0 (1-3) 2.0 (1-3) 0.96 
Low (score 0) 
Intermediate (score 1) 
High (score 2-6) 
63 (10.5) 
165 (27.5) 
373 (62.1) 
67 (13.0) 
112 (21.7) 
337 (65.3) 
0.06 
CHA2DS2-VASC, median (IQR) 4 (2-5) 4 (2-5) 0.99 
Low (score 0) 
Intermediate (score 1) 
High (score 2-6) 
16 (2.7) 
53 (8.8) 
532 (88.5) 
20 (3.9) 
54 (10.5) 
442 (85.7) 
0.20 
HAS-BLED, median (IQR) 2.0 (1-2) 2.0 (1-2) 0.21 
Low (score 0) 
Intermediate (1-2) 
High (≥3) 
45 (7.5) 
451 (75.0) 
105 (17.5) 
38 (7.4) 
376 (72.9) 
102 (19.8) 
0.60 
CCI, median (IQR) 5.0 (4-7) 5.0 (4-6) 0.43 
0 50 (8.3) 46 (8.9) 0.43 
1-2 26 (4.3) 16 (3.1)  
3-4 134 (22.3) 132 (25.6)  
≥5 391 (65.1) 322 (62.4)  
AF duration, n (%)    
New onset 153 (26.2) 159 (31.5) 0.06 
Old 430 (73.8) 346 (68.5)  
AF, atrial fibrillation; CCI, Charlson comorbidity index; CHF, congestive heart failure; DVT, deep vein 
thrombosis; HTN, hypertension; MI, myocardial infarction; IQR, interquartile range; SD, standard deviation. 
*= P<0.05 
 
3.3.2 Anticoagulant prescribing pattern among patients with NVAF at discharge 
Among those anticoagulated in the total population (n=601/1117), the majority of the patients 
were taking warfarin (61.7%) followed by a combination of warfarin and antiplatelet (24.8%), 
dabigatran (2.5%), and dabigatran plus antiplatelet (0.7%). The proportion of eligible patients 
treated with anticoagulant alone, combination therapy, antiplatelet alone or no treatment at 
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various levels of stroke risk (CHADS2) is shown in Figure 3.1. Of patients with a high-risk of 
stroke (CHADS2 ≥2), 52.5% (n=373/710) were prescribed anticoagulant therapy. Two hundred 
and sixty-four (37.2%) of these patients were prescribed antiplatelet therapy and seventy-three 
(10.3%) patients were not on any antithrombotic treatment. Physician’s decision was the most 
commonly documented reason for not providing anticoagulant treatment at discharge to the 
eligible patients at high-risk of stroke (n=44; 6.2%), followed by ‘patient refusal’ (n=22; 3.1%), 
‘falls risk’ (n=22; 3.1%), ‘non-adherence’ (n=5; 0.7%), and ‘adverse drug reaction’ (n=3; 0.4%). 
Among those with a high-risk of stroke (CHADS2 ≥2), only 3.2% (n=23) had a HAS-BLED 
score that exceeded their CHADS2 score. Among those at lower risk of stroke (CHADS2=0) and 
receiving anticoagulant therapy, only 6.2% (n=8/130) had a history of embolic diseases other 
than AF where anticoagulation may have been indicated. 
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Figure 3.1 Antithrombotic prescribing pattern among patients with NVAF based on CHADS2 score 
 
When we compared the rate of anticoagulant prescribing among high-risk patients to that 15 
years ago in Tasmania, there appeared to be an increase in the rate (52.5% vs. 42.1%) of 
prescribing. Nearly 10% of the high-risk patients did not receive any therapy (18.2% 15 years 
ago) and 48.5% of low-risk patients were anticoagulated (14.2% in the earlier cohort). 
 
3.3.3 Factors associated with anticoagulant prescribing at discharge  
We considered patients with NVAF and without CIs as eligible for anticoagulant therapy. 
Multivariate logistic regression included seven variables: age, gender, stratified CHADS2 (with 
CHADS2=0 as reference category), history of diabetes, CHF, embolic disease, and pre-admission 
AF. Younger age (odds ratio [OR] 0.99, 95% CI 0.97-1.0; P=0.04), CHADS2=1 (OR 1.68, 95% 
CI 1.07-2.63; P=0.02), CHF (OR 1.56, 95% CI 1.12-2.15; P=0.008) and embolic disease history 
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(OR 1.77, 95% CI 1.09-2.86; P=0.02) were independently associated with anticoagulant 
prescribing (Table 3.2).  
 
 Table 3.2 Univariate and multivariate logistic regression of risk factors for anticoagulant prescribing among 
eligible patients with NVAF 
Odds of 
anticoagulant 
prescribing 
Univariate OR (95% CI) P-value Multivariate OR (95% CI) P-value 
Age 0.99 (0.98-1.0) 0.01* 0.99 (0.97-1.0) 0.04* 
Sex     
Female 0.76 (0.60-0.97) 0.03* 0.84 (0.65-1.08) 0.18 
CHADS2     
0 (ref)     
1 1.57 (1.03-2.38) 0.04* 1.68 (1.07-2.63) 0.02* 
2 1.08 (0.72-1.60) 0.72 1.13 (0.70-1.83) 0.62 
≥3 1.30 (0.87-1.95) 0.20 1.19 (0.69-2.03) 0.53 
Comorbidities     
CHF 1.51 (1.13-2.01) 0.005* 1.56 (1.12-2.15) 0.008* 
HTN 1.10 (0.86-1.41) 0.46   
Diabetes 1.30 (0.97-1.74) 0.08 1.25 (0.90-.1.75) 0.19 
CVD 0.91 (0.67-1.23) 0.55   
Embolic history 1.76 (1.10-2.81) 0.02* 1.77 (1.09-2.86) 0.02* 
AF onset            
New (ref)     
Old 1.29 (0.99-1.68) 0.06 1.18 (0.90-1.55) 0.25 
AF, atrial fibrillation; CHF, congestive heart failure; CVD, cerebrovascular disease; CI; confidence interval; HTN, 
hypertension; NVAF, non-valvular atrial fibrillation; OR, odds ratio. 
  
3.4 Discussion 
Nearly two-thirds of our patient cohort was at high-risk of stroke. We observed underutilisation 
of anticoagulant therapy among these eligible high-risk patients. Our data suggest that, despite an 
improvement in prescribing of anticoagulant therapy over the past 15 years, there remains 
significant potential for reduction in stroke outcomes with improved use of antithrombotic 
prophylaxis in the Tasmanian AF population. Despite guideline recommendations, we did not 
observe CHADS2 ≥2 as a significant predictor of anticoagulant prescribing in our population.  
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Underuse of anticoagulant therapy among high-risk groups has been frequently reported.(103, 
116, 194, 212) In our study, only half of the patients in the high-risk group were receiving 
anticoagulant treatment. There was an apparent preference for lone antiplatelet therapy, with 
nearly one-third of our high-risk population receiving this therapy.  
 
The observed improvements in anticoagulant prescribing among high-risk AF patients in 
Tasmania most likely reflect increased focus on the importance of effective thromboprophylaxis 
as recommended in international guidelines, as well as results of previous local intervention 
studies.(7, 16, 208) In contrast, we observed that the proportion of low-risk patients receiving 
anticoagulant therapy was higher now than 15 years ago. This appears to reflect current trends, 
however, as use of anticoagulant therapy in this group was similar to the GARFIELD study.(103) 
Embolic diseases other than AF may have resulted in some patients at low risk of stroke 
receiving anticoagulant therapy in our study, as embolic history was an independent predictor of 
anticoagulation. Alternatively, physicians’ clinical judgement of stroke risk may have compelled 
them to consider factors beyond those included in CHADS2.(103)  
 
Several observational studies have reported on factors influencing anticoagulant 
prescribing patterns.(213, 214) Although prescribing guidelines for patients with intermediate 
risk of stroke were unclear at the time of our study (antiplatelet or anticoagulant therapy was 
indicated), (7, 16) the association between intermediate stroke risk (CHADS2 score of 1) and 
anticoagulation use, instead of high risk (CHADS2 ≥2), relative to a CHADS2 score of 0 was 
surprising. Existing guidelines clearly recommended prescription of anticoagulant therapy 
among those with a CHADS2 ≥2,(7, 16) but in alignment with previous studies conducted in 
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China and Turkey (210, 211) we did not find CHADS2 ≥2 as a predictor of anticoagulant 
prescribing. We hypothesised that this finding may have been due to high bleeding risk among 
these patients (given the overlap between stroke and bleeding risk factors), but only 3.2% of 
patients within this group had a HAS-BLED score higher than their CHADS2 score. We 
identified physicians’ decision to be the most common reason for not prescribing anticoagulant 
treatment to high-risk patients without any CIs. Bleeding is one of the most feared complications 
of anticoagulant use among treating physicians;(205) this may have influenced physicians’ 
prescribing decisions in our study. This apparent discrepancy may further highlight the 
previously documented issue of quantifiable versus perceived bleeding risk by clinicians, and 
this issue requires further study if we are to make meaningful improvements in underprescribing 
of anticoagulants in patients at high risk of stroke.  
 
A history of CHF and embolic disease, and younger age were the only other independent 
predictors of anticoagulant prescribing in our population. CHF has been previously associated 
with a higher rate of oral anticoagulation use,(212) and previous TE is now clearly 
acknowledged as a risk factor for stroke through its inclusion in the CHA2DS2-VASc scoring 
system.(20) We observed older age as a negative predictor for anticoagulant prescribing. Studies 
have identified underuse of anticoagulant therapy among elderly people due to the fear of 
bleeding.(197, 215) In contrast, benefits of anticoagulant therapy have been proven in clinical 
trials conducted among elderly patients (204, 216) and hence their use should not be discounted 
among elderly high-risk groups.  
 
 
 
73 
 
3.5 Conclusions 
Our results suggest that there has been some improvement in the use of anticoagulant therapy 
among high-risk patients with AF over the past 15 years. Despite this improvement, further gains 
are required, and improved adherence to stroke risk stratification schemes for antithrombotic 
prophylaxis in AF could potentially reduce stroke outcomes in our population.  
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Chapter 4: Hospital Readmission for Bleeding or Thromboembolic 
Complications in Patients with Newly Diagnosed Atrial Fibrillation 
 
4 Abstract 
This study was designed to examine the rates of, and factors associated with, hospital 
readmissions due to bleeding or thromboembolism (TE) among patients newly diagnosed with 
AF. We recruited patients admitted to the Royal Hobart Hospital in Tasmania, Australia, with 
newly diagnosed AF between January 2011 and June 2012. Patients were then followed for at 
least 18 months from the discharge date of their index admission to identify subsequent 
admissions for major bleeding or TE. In total, 257 patients (≥18 years) were included. The rates 
per 100 person-years (PY) of bleeding and TE-related readmissions within 3 months were 4.8 
(95% CI 2.2-7.5) and 8.1 (95% CI 4.8-11.4), respectively. The rates per 100 PY of bleeding and 
TE-related readmissions during a mean of 2.1 years’ follow-up were 1.5 (95% CI 0.02-3.0) and 
3.7 (95% CI 1.4-6), respectively. Patients with peripheral vascular disease (PVD) (odds ratio 
(OR) 7.7, 95% CI 1.2-49.3) and renal impairment (OR 14.7, 95% CI 2.2-99.5) were more likely 
to be readmitted for bleeding, while those with a history of myocardial infarction (MI) (OR 6.3, 
95% CI 2.2-18.1) were more likely to be readmitted for TE during longer-term follow-up. The 
rates of bleeding or TE-related readmissions were high in the initial 3 months in this cohort. 
Patients with PVD and renal impairment were at higher risk of bleeding and those with history of 
MI were at higher risk of TE during longer-term follow-up. These patients should be a focus of 
interventions to reduce adverse events in AF. 
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4.1 Introduction 
Atrial fibrillation (AF) is a major risk factor for stroke and thromboembolism (TE).(12) The risk 
increases further with a previous history of stroke or transient ischaemic attacks (TIA), and a 
number of other known risk factors.(13) Stroke prevention is therefore a vital component of AF 
management. All contemporary guidelines recommend stroke prophylaxis with antithrombotic 
agents in people with AF and at least one other risk factor for stroke.(7, 16) Importantly, as 
bleeding is the most feared complication of oral anticoagulant therapy (OAC) therapy, the choice 
of appropriate antithrombotic therapy for stroke prevention in patients with AF requires a 
balance between the risk of stroke and risk of bleeding.(7)  
 
AF is known to be associated with a high rate of hospital readmission (217, 218) due to 
complications including bleeding and TE. One population-based study of warfarin-treated 
patients with AF in the United Kingdom reported the incidence of vascular events (myocardial 
infarction (MI), stroke or systemic arterial peripheral embolism) and bleeding-related 
hospitalisations to be 3.8 per 100 patient-years and 3.3 per 100 patient-years, respectively.(219) 
It is established that the rates of bleeding or TE-related adverse effects are highest in the first 3 
months of anticoagulant treatment in patients with AF.(220, 221) It has been suggested that the 
excess bleeding and mortality risk during initiation of anticoagulant therapy is a result of the 
unmasking of occult lesions or problems with International Normalised Ratio (INR) monitoring 
and warfarin dose adjustments during this period.(220) Monitoring the outcomes of patients with 
AF after initiation of antithrombotic treatment thus could play a significant role in minimising 
fatal bleeding and TE-related events in these patients. Although there are data regarding 
antithrombotic treatment patterns among patients with AF in Australia (117, 203), the data are 
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limited with respect to the rates of, and risk factors associated with, bleeding or TE-related 
hospitalisation. Our study examined the rates of readmissions due to bleeding or TE during 
short-term and longer-term follow-up periods among patients with newly diagnosed AF at the 
major hospital in Tasmania, Australia. We also identified the risk factors for readmission due to 
bleeding or TE during longer-term follow-up period. 
 
4.2 Methods 
4.2.1 Study design 
We reviewed the records of patients aged ≥ 18 years with a primary or additional diagnosis of 
AF at discharge from the Royal Hobart Hospital (RHH), between 1
st
 January 2011 and 30
th
 June 
2012. The RHH is a 500-bed teaching hospital for the southern region of Tasmania (population ≈ 
260,000).(199) For this study, patients with either newly diagnosed non-valvular or valvular AF 
(Australian Refined Diagnosis-Related Group (AR-DRG) code I48: atrial fibrillation or flutter) 
during their index admission were included. Patients were excluded if they had only one episode 
of AF that reverted spontaneously or upon cardioversion without any documented recurrences, as 
stroke prophylaxis is not warranted in these groups of patients. Data collected at baseline 
included patient demographics, medication on admission and discharge, previous medical 
history, relevant laboratory data, and discharge diagnoses.  
 
The CHADS2 and CHA2DS2-VASc scores were used to estimate stroke risk. The 
CHADS2 score was derived by allocating one point each for congestive heart failure (CHF), 
hypertension (HTN), age ≥75 years or diabetes, and two points for previous stroke or TIA.(17) 
The CHA2DS2-VASc score was calculated by assigning one point each to CHF, HTN, diabetes, 
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vascular disease (prior MI, peripheral artery disease or aortic plaque), age 65-74 years or female 
gender, and two points for age ≥75 years and previous stroke or TIA or TE.(20) The HAS-BLED 
score, used to estimate bleeding risk, was derived by allocating one point each for HTN, 
abnormal renal function (dialysis, transplant, serum Cr>200µmol/L), abnormal liver function 
(cirrhosis or bilirubin>2×normal or AST/ALT/AP>3×normal), previous stroke, bleeding pre-
disposition, age >65  years, labile INRs (defined as documented unstable/high INRs), the use of 
drugs predisposing patients to bleeding (e.g. non-steroidal anti-inflammatory drugs [NSAIDs]) 
and alcohol use (>8 drinks per week).(33) CHA2DS2-VASc and HAS-BLED were included in 
our analysis to assist in our interpretation of results and provide a modern context, although it is 
acknowledged that they were not available to clinicians during the study period. The Charlson 
Comorbidity Index (CCI) was used as a measure of comorbidity.(200)  
 
For the purposes of this analysis, patients were grouped according to the antithrombotic 
therapy (anticoagulant and/or antiplatelet medications) they received at discharge from their 
index admission. The ‘antiplatelet’ group consisted of patients receiving aspirin, clopidogrel, 
prasugrel, dipyridamole or ticagrelor, either alone or in combination with each other but not in 
combination with an anticoagulant. The ‘lone anticoagulant’ group consisted of patients 
receiving one of warfarin, dabigatran, heparin, fondaparinux or enoxaparin at discharge. Patients 
taking a combination of an anticoagulant medication with an antiplatelet agent constituted the 
‘combination therapy’ group. Our definition of ‘anticoagulant therapy’ for this study comprised 
anticoagulant therapy, with or without concomitant antiplatelet therapy. We considered a 
patient’s index admission as their first admission within our data collection period with a 
diagnosis of AF that met the study’s inclusion criteria. During short-term follow-up, patients 
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were followed for 3 months from time of hospital discharge after their index admission with 
newly diagnosed AF or until the occurrence of a primary outcome or death, whichever came 
first. Similarly, for longer-term follow-up, patients were followed for at least 18 months from 
time of hospital discharge after their index admission with newly diagnosed AF, or until the 
occurrence of a primary outcome, death or December 31, 2013, whichever occurred first. Our 
primary outcomes were readmissions due to: 1) major bleeding, including haemorrhagic stroke 
requiring hospitalisation, and 2) TE (ischaemic stroke and systemic embolism, MI and TIA). 
Systemic embolism (SE) included an acute vascular occlusion of the extremities or any organ 
(kidneys, mesenteric arteries, spleen, retina or grafts). Major bleeding was defined as fatal or 
symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, 
retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome, and/or 
bleeding causing a fall in haemoglobin level of 20g/L (1.24 mmol/L) or more, or leading to 
transfusion of at least two units of packed red blood cells.(222) 
 
We calculated the incidence rate (number of events per 100 person-years [PY]) of each 
event for each treatment group and overall by dividing the numbers of major bleeding or TE 
events by the PY of exposure.  
 
4.2.2 Statistical analysis 
Data were analysed using SPSS version 21 (Prentice Hall, USA). Continuous variables were 
expressed as mean ± standard deviation (SD). Categorical variables were expressed as 
frequencies and percentages. The rates of major bleeding and TE among different antithrombotic 
therapies were compared using the Kaplan-Meier method and log-rank test. In order to identify 
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the predictors of hospitalisation due to major bleeding or TE, we calculated odds ratio (ORs) and 
95% confidence intervals (CIs) using binary logistic regression analysis and considered variables 
with a P value ≤0.2 as candidates for multivariate analysis. A multivariate analysis was carried 
out using the ‘Enter’ method to determine the independent predictors for longer-term 
readmission due to major bleeding or TE. The a priori level of significance was <0.05 for all 
analyses.  
 
Ethics approval for the project was obtained from the Tasmanian Health and Medical 
Human Research Ethics Committee. 
 
4.3 Results 
4.3.1 Baseline data  
The medical records of 1245 patients were reviewed, of whom 777 were included and 468 were 
excluded (episode of AF that reverted spontaneously or upon cardioversion: 228, developed AF 
as a short-term complication: 179, no documented AF [coding error]: 61). Forty-seven (6.1%) 
index admissions were excluded due to death of the patient or unavailability of their records. Of 
those discharged alive, 35.2% (n=257) had newly diagnosed AF and were thus included in this 
analysis (Figure 4.1). The characteristics of the patients with newly diagnosed AF are shown in 
Table 4.1. 
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Figure 4.1. Study flowchart 
Abbreviation: AF, atrial fibrillation 
  
Patients with AF aged  
≥18 years (n=1245) 
n=777 
Patients with newly 
diagnosed AF 
followed-up 
n=257 
1. Death or unavailability of 
records (n=47) 
2. Old AF (n=473) 
 
1. AF that reverted 
spontaneously or upon  
cardioversion 
 
2. AF as a short-term 
complication 
 
3. No documented AF 
(n=468)  
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 Table 4.1 Baseline characteristics of New AF patients enrolled in TAF study 
Variables All patients (n=257) 
Age in years, Mean ± SD 74.4  ± 12.3 
Men, n (%) 134 (52.1) 
Medical history, n (%)   
Hypertension 177 (68.9) 
Ischaemic heart disease  86 (33.5) 
Chronic respiratory disease 55 (21.4) 
Diabetes 45 (17.5) 
Cerebrovascular disease 42 (16.3) 
Myocardial infarction  35 (13.6) 
Congestive heart failure 19 (7.4) 
Peripheral vascular disease 12 (4.7) 
Embolic events (DVT, Pulmonary embolism) 9 (3.5) 
History of bleeding  6 (2.3) 
Valvular heart disease, n (%) 26 (10.1) 
CCI (classic), Mean ± SD 4.6  ± 2.3 
CHADS2, Mean ± SD 1.8  ± 1.2 
Low (score 0) 39 (15.2%) 
Intermediate (score 1) 66 (25.7%) 
High (score 2-6) 152 (59.1%) 
CHA2DS2-VASc, Mean ± SD 3.3  ± 1.7 
Low (score 0) 11 (4.3%) 
Intermediate (score1) 31 (12.1%) 
High (score 2-9) 215 (83.7%) 
HAS-BLED, Mean  ± SD 1.6  ± 0.9 
Low (score 0) 27 (10.5%) 
Intermediate (score 1-2) 192 (74.7%) 
High (score ≥3) 38 (14.8%) 
Antithrombotic therapy (on admission), n (%)  
Antiplatelet therapy  128 (49.8) 
Anticoagulant therapy  10 (3.9) 
AP/AC combination 7 (2.7) 
No antithrombotic therapy 112 (43.6) 
Reason for index admission, n (%)  
Related to AF 
Bleeding 
112 (43.6) 
3 (1.2) 
Thromboembolism 25 (9.7) 
Other cardiovascular conditions 
None of the above 
54 (21.0) 
63 (24.5) 
AP/AC, antiplatelet and anticoagulant; AF, atrial fibrillation; CCI, Charlson comorbidity index; CHADS2, 
congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, previous stroke/transient ischaemic attack; 
CHA2DS2-VASC, congestive heart failure, hypertension, age ≥75, diabetes mellitus, stroke/transient ischaemic 
attack/systemic embolism, vascular disease, age 65-74 years, sex category; DVT, deep vein thrombosis; HAS-
BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or pre-disposition, labile international 
normalised ratio, Age >65 years, drugs/alcohol concomitantly; SD, standard deviation. 
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4.3.2 Incidence rates of major bleeding and TE 
During the 3-month follow-up period, 3 bleeding and 5 TE events were identified; while during a 
mean of 2.1 years’ follow-up, 8 bleeding and 19 TE events were recorded. A total of 61.95 PY 
for bleeding outcomes, and 61.88 PY for TE outcomes were identified for short-term follow-up 
and a total of 528.91 PY for bleeding outcomes, and 518.69 PY for TE outcomes were identified 
for longer-term follow-up. The incidence rates of readmission due to bleeding or TE during the 
two follow-up periods are shown in Table 4.2. Incidence rates of bleeding or TE events based on 
antithrombotic therapy during the two follow-up periods are shown in Table 4.3. We did not 
observe significant differences in bleeding or TE outcomes among different treatment categories.  
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 Table 4.2 Event rates of major bleeding and thromboembolic events during short and longer-term follow-up periods 
Events 3 months 
events 
a
Incidence rate per 100 person 
years; 
b
% (95% CI)  
18 months events 
a
Incidence rate per 100 person years; 
b
% 
(95% CI)  
Major bleeding  3 4.8 (2.2-7.5) 8 1.5 (0.02-3.0) 
GIB 1 1.6 (0.1-3.2) 3 0.6 (-0.4-1.5) 
ICH - - 1 0.2 (-0.3-0.7) 
Others* 2 3.2 (1.1-5.4) 4 0.8 (0.3-1.8) 
Thromboembolic  5 8.1 (4.8-11.4) 19 3.7 (1.4-6) 
Ischaemic stroke/SE 3 4.9 (2.2-7.5) 11 2.1 (0.4-3.9) 
MI   1 1.6 (0.1-3.2) 7 1.2 ( -0.1-2.8) 
TIA 1 1.6 (0.1-3.2) 1 0.2 (-0.3-0.7) 
GIB, gastrointestinal bleeding; ICH, intracranial haemorrhage; MI, myocardial infarction; SE, systemic embolism; TIA, transient ischaemic attack 
*Others: epistaxis, retroperitoneal bleeding.  
a                                    
                                      
                                       
     
b% (95% CI): Incidence rates presented with 95% confidence intervals.  
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 Table 4.3 Major bleeding and thromboembolic readmission rates according to antithrombotic therapy on discharge 
No. of major bleeding readmissions NT (27) AP (114) AC (60) Combination (56) P value 
3 months  0 1 0 2 0.27 
Person-years of follow-up 6.4 27.8 14.6 13.2  
a
Incidence rate/100 person-years, 
b
% (95% CI) 0 3.6 (0.2-7.0) 0 15.2 (4.3-22.0)  
18 months  0 3 1 4 0.25 
Person-years of follow-up 52.7 238.9 122.5 114.8  
a
Incidence rate/100- person-years, 
b
% (95% CI) 0 1.3 (-0.8-3.4) 0.8 (-1.5-3.1) 3.5 (-1.2-8.3)  
No. of thromboembolic readmissions      
3 months 1 1 1 2 0.58 
Person-years of follow-up 6.3 27.8 14.6 13.3  
aIncidence rate/100- person-years, b% (95% CI) 7.0 (-2.6-16.6) 3.6 (0.2-7.0) 6.9 (0.5-13.3) 15.1 (5.7-24.5)  
18 months 4 8 3 4 0.26 
Person-years of follow-up 48.4 232.4 122.3 115.5  
aIncidence rate/100- person-years, b% (95% CI) 8.3 (-2.1-18.7) 3.4 (0.1-6.7) 2.5 (-1.5-6.5) 3.5 (-1.3-8.3)  
NT, no therapy; AP, antiplatelet therapy; AC, anticoagulant therapy; Combination: (AP+AC) 
a                                
                                        
                                       
     
b% (95% CI): Incidence rates presented with 95% confidence intervals. 
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4.3.3 Predictors of major bleeding and TE-related readmission 
Multivariate logistic regression performed to identify predictors of longer-term readmission due 
to bleeding included three variables: CHF, peripheral vascular disease (PVD) and discharge 
estimated glomerular filtration rate <30 mL/min/1.73m
2
 (eGFR <30). Notably, we did not any 
relationship between HAS-BLED score and bleeding-related readmission in our analysis 
(P=0.83). Longer-term readmission due to bleeding was independently associated with history of 
PVD (OR (odds ratio) 7.7, 95% CI 1.2-49.3; P=0.03) and an eGFR <30 (OR 14.7, 95% CI 2.2-
99.5; P=0.006) (Table 4). All of the patients with the history of PVD and readmitted due to 
bleeding were taking combination therapy at the time of their readmission although 
antithrombotic therapy itself did not predict readmission. Similarly, multivariate regression 
carried to identify predictors of longer-term readmission due to TE included four variables: 
history of HTN, MI, diabetes and cerebrovascular disease. Prior history of MI was the only risk 
factor independently associated with an increased likelihood of longer-term readmission due to 
TE (OR 6.3, 95% CI 2.2-18.1; P <0.001) (Table 4.4).  
  
Table 4.4 Multivariate analysis of association between potential predictors and readmission for longer-term 
major bleeding or thromboembolism 
Major bleeding 
readmissions 
Comorbidities 
a
OR (95% CI) P value 
 Peripheral vascular disease 7.7 (1.2-49.3) 0.03b 
 Discharge eGFR   
 <30  14.7 (2.2-99.5) 0.006
b
 
 30-60 2.8 (0.4-18.2) 0.28 
 >60 (ref)   
Thromboembolic 
readmissions    
Comorbidities 
a
OR (95% CI) P value 
 Myocardial infarction 6.3 (2.2-18.1) <0.001b 
 eGFRr, estimated glomerular filtration rate in mL/min/1.73 m2  
aOR (95% CI): odds ratio presented with 95% confidence intervals. 
b
P < 0.05 
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4.4 Discussion 
Our 3-month event rates per 100 PY for major bleeding and TE were higher than the rates at 
longer-term follow-up. The risk of bleeding in particular has been found to be highest early in 
the course of anticoagulant therapy.(223) Other real-world studies have also reported that the 
rates of bleeding or TE-related adverse events are higher in the first 3 months of anticoagulant 
treatment in patients with AF.(220, 221) Poor anticoagulation control after hospital initiation of 
warfarin has been well reported, (224) and we hypothesize that this may have contributed to our 
higher 3-month event rates. We were unable to demonstrate a difference in event rates between 
agents, however, potentially due to the low overall number of events; a larger study would be 
required to confirm this hypothesis. 
 
In randomized controlled trials involving patients with AF, the incidence of major 
bleeding due to antithrombotic treatment was reported to range between 1 and 3% per person-
year.(74, 81, 82, 225) When compared to data reported in the recent clinical trials comparing 
direct acting oral anticoagulants to warfarin, (66, 71, 74, 76) our longer-term rates per 100 PY of 
major bleeding (1.5 vs. 0.50-4.20/year) and stroke/SE (2.1 vs. 1.10-2.20/year) were comparable. 
In comparing our rates to a ‘real-world’ study, while the longer-term rate per 100 PY of 
stroke/SE event was comparable (2.1 vs. 2.97%), our rate per 100 PY of major bleeding event 
was lower than the rate  previously reported (1.5 vs. 6.22%).(226)  
 
Our study also examined the risk factors associated with major bleeding or TE-related 
readmissions during a longer-term follow-up period in patients with AF. We identified that 
history of MI was the only predictor for TE-related readmission. The risk of stroke and/or the 
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composite thromboembolism endpoint (stroke, TIA, or systemic embolism) has been found to 
increase independently in the presence of vascular disease in patients with AF, (34) which is also 
reflected in the recent inclusion of MI as a risk factor for stroke in CHA2DS2-VASc. Guidelines 
regarding combination therapy in patients with AF and unstable coronary artery disease currently 
vary, (16, 227) and our results suggest a need for a particular focus on optimal prescribing in this 
group of patients.  
 
Factors such as older age, alcohol excess, anaemia, and heart failure have been found as 
independent predictors of bleeding.(228) We instead observed a history of PVD and severe renal 
impairment as significant predictors of major bleeding-related readmissions during our longer-
term follow-up. It should be acknowledged, however, that the confidence intervals are relatively 
wide, reflecting our sample size and the incidence of outcome measures. Vascular disease, 
including PVD, has been recently introduced into the risk assessment for patients with AF due to 
its inclusion in the CHA2DS2-VASc score. A history of PVD has not previously been associated 
with an increased risk of bleeding events in patients with AF. While this finding is likely due to 
the use of combination anticoagulant/antiplatelet therapy in this group, a larger study is again 
needed to confirm such a result. In the meantime, our finding suggests that closer monitoring is 
necessary while treating patients with AF and a history of PVD. Rates of bleeding have been 
found to increase with reducing eGFR, regardless of sex, age, or anticoagulant therapy.(229) Our 
observation that patients with reduced eGFR were more likely to suffer from major bleeding-
related readmissions suggests the fact that patients with AF and renal impairment should also be 
closely monitored for major bleeding-related outcomes. Trials of OAC therapy (including direct 
acting oral anticoagulants) are required among these patients to establish the balance of efficacy 
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vs. safety of anticoagulant therapy as the majority of AF trials have excluded patients with 
chronic kidney disease.(229)  
 
4.5 Conclusions 
The prevalence of major bleeding or TE-related readmissions was high in initial 3 months in this 
cohort. Patients with a history of PVD and renal impairment were at higher risk of major 
bleeding and those with MI were at higher risk of TE during longer-term follow-up. Our findings 
suggest that these risk factors should be considered as ‘red flags’ when managing patients with 
AF, and patients with these conditions should receive special attention when managing 
concomitant AF. In fact, these patient groups are a potential target for intervention in future AF 
studies so as to minimise the incidence of major bleeding or TE-related hospitalisations.  
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
 
89 
 
Chapter 5: Antithrombotic usage patterns and outcomes among elderly 
patients diagnosed with atrial fibrillation in Tasmania 
 
5 Abstract 
Longer-term follow-up data for elderly patients diagnosed with atrial fibrillation (AF) is sparse 
in Australia. This study was designed to compare the patient characteristics, antithrombotic 
prescribing patterns, and rates of major bleeding and thromboembolic (TE) outcomes between 
older and younger patients diagnosed with AF. We recruited patients admitted to the Royal 
Hobart Hospital in Tasmania, Australia, with diagnosed AF between January 2011 and June 
2012. These patients were then followed for at least 18 months from the discharge date of their 
index admission to identify subsequent admissions for major bleeding or TE. In total, 730 
patients (≥18 years) were included, of whom 374 (51.2%) were aged ≥75. Among high-risk 
patients aged ≥75 years, only 51.8% received anticoagulant treatment (vs. 64.6% in the younger 
group; P=0.02). After a mean follow-up of 2.2 years, elderly patients were observed to be at 
higher risk of major bleeding (hazard ratio (HR) 3.2, 95% CI) 1.4-7.5, P=0.004) but the 
incidence of TE did not differ significantly (HR 1.5, 95% CI 0.9-2.7, P=0.15) between the 
groups. Elderly patients prescribed anticoagulant therapy were at significantly higher risk of 
major bleeding (HR 3.0, 95% CI 1.1-8.3, P=0.02) but at similar risk of TE (HR 0.9, 95% CI 0.4-
1.8, P=0.69) compared to those on no anticoagulant therapy. In this study, anticoagulant therapy 
was underused among high-risk elderly patients with AF compared to their younger counterparts. 
Elderly patients had higher incidence of major bleeding but similar risk of TE compared to 
younger patients in this cohort. 
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5.1 Introduction 
Atrial fibrillation (AF) is associated with increased risks of cardiovascular and cerebrovascular 
complications including myocardial infarction (MI) and cardio-embolic stroke.(230, 231) 
Advanced age has been shown to be one of the major risk factors for AF-associated stroke in 
patients with AF. A number of studies have shown that AF is more common in people over the 
age of 65 years than their younger counterparts. AF is present in 0.12-0.16% of those younger 
than 49 years, in 3.7-4.2% of those aged 60-70 years, and in 10-17% of those aged 80 years or 
older.(90, 232) In the Framingham Study, 23.5% of strokes in individuals aged 80 years or older 
were attributable to AF.(233) Recent guidelines from Europe, America and other countries 
throughout the world recommend oral anticoagulant (OAC) prophylaxis in patients with AF and 
at high risk of stroke, (CHA2DS2-VASc ≥2).(6, 7, 234) However, use of OAC in the elderly is 
challenging as both stroke and bleeding risk increase with age.  
 
Although the benefits of antithrombotic therapy in the elderly are well established, the 
elderly are more vulnerable to adverse effects of antithrombotic drugs. It has been shown that 
treatment with warfarin under careful monitoring is associated with a 0.3-0.5% increased risk of 
major bleeding per year compared with controls.(235) These rates may be higher in routine 
clinical practice, taking into account that data are mainly derived from younger cohorts and well-
controlled patients rather than those observed in real life. In particular, there is a tendency 
towards a 2 to 3-fold increase in bleeding and intracranial haemorrhages (ICH) among elderly 
patients.(235, 236) Surveys have consistently revealed patient age as a deterrent to the use of 
OAC in AF. Physicians are reluctant to prescribe anticoagulants in elderly patients due to high 
risk of falls and risk of traumatic ICH, poor compliance, difficulty in monitoring, cognit ive 
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impairment and risk of interaction with multiple other drugs.(132, 133) These issues may 
provide explanations for the substantial underutilisation of vitamin K antagonists in the elderly 
population. OAC therapy continues to be underutilised in older adults despite compelling 
evidence of benefits in stroke reduction in this age group. Studies have shown that, 30-50% of 
older adult patients without contraindication to OAC are not receiving anticoagulant 
therapy.(237, 238) However, even if elderly individuals have characteristics that may place them 
at higher risk for bleeding, they also have characteristics that make them more likely to benefit. 
The BAFTA (Birmingham Atrial Fibrillation Treatment of the Aged) trial, a randomized 
comparison of warfarin versus aspirin in 973 patients with AF age ≥75 years, revealed that the 
yearly risk of the combined primary end point of stroke, ICH, or clinically significant embolism 
was 1.8% in patients who received warfarin and 3.8% in those who received aspirin (relative 
risk: 0.48, 95% CI: 0.28 to 0.80, P<0.003).(204) Accordingly, age alone should not be a 
contraindication to OAC use as elderly patients with AF may benefit most from anticoagulation. 
Hence, anticoagulation in elderly patients requires careful assessment of risk of stroke against an 
equally high risk of major bleeding. Studies regarding use and outcomes of OAC in the elderly 
patients from routine clinical settings are limited throughout the world. To date, longer-term 
follow-up data for elderly patients diagnosed with AF is sparse in Australia. In this study we 
sought to examine and compare the patient characteristics, antithrombotic prescribing patterns, 
and rates of major bleeding or TE outcomes during longer-term follow-up between older and 
younger patients diagnosed with AF in Tasmania. 
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5.2 Materials and Methods 
5.2.1 Study design 
We reviewed the records of patients aged ≥18 years with a primary or secondary diagnosis of AF 
at discharge from the Royal Hobart Hospital (RHH), between 1
st
 January 2011 and 30
th
 June 
2012. The RHH is a 500-bed teaching hospital for the southern region of Tasmania (population ≈ 
260,000).(199) Patients diagnosed with either non-valvular or valvular AF (Australian Refined 
Diagnosis-Related Group code I48: atrial fibrillation or flutter) during their index admission 
were included for this study. We divided patients into two age groups - a younger group aged 
<75 and an older group aged 75 or above. We excluded patients if they had only one episode of 
AF that reverted spontaneously or upon cardioversion without any documented recurrences, as 
stroke prophylaxis is not warranted in these groups of patients.  
 
The CHADS2 and CHA2DS2-VASc scores were used to estimate stroke risk. We derived 
the CHADS2 score by allocating one point each for congestive heart failure (CHF), hypertension 
(HTN), age ≥75 years or diabetes, and two points for previous stroke or transient ischaemic 
attack (TIA).(17) The CHA2DS2-VASc score was calculated by assigning one point each to 
CHF, HTN, diabetes, vascular disease (prior MI, peripheral artery disease or aortic plaque), age 
65-74 years or female gender, and two points for age ≥75 years and previous stroke or TIA or 
TE.(20) We derived the HAS-BLED score, used to estimate bleeding risk, by allocating one 
point each for HTN, abnormal renal function (dialysis, transplant, serum Cr>200µmol/L), 
abnormal liver function (cirrhosis or bilirubin>2×normal or AST/ALT/AP>3×normal), previous 
stroke, bleeding pre-disposition, age >65 years, labile INRs (defined as documented 
unstable/high INRs), the use of drugs predisposing patients to bleeding (e.g. non-steroidal anti-
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inflammatory drugs [NSAIDs]) and alcohol use (>8 drinks per week).(33) CHA2DS2-VASc and 
HAS-BLED were included in our analysis to assist in our interpretation of results and provide a 
modern context, although it is acknowledged that they were not available to clinicians during the 
study period. The Charlson Comorbidity Index (CCI) was used as a measure of 
comorbidity.(200)  
 
Patients receiving aspirin, clopidogrel, prasugrel, dipyridamole or ticagrelor, either alone 
or in combination with each other but not in combination with an anticoagulant comprised the 
‘antiplatelet’ treatment group. Patients receiving one of warfarin, dabigatran, heparin, 
fondaparinux or enoxaparin at discharge constituted ‘lone anticoagulant’ group. Patients taking a 
combination of an anticoagulant medication with an antiplatelet agent constituted the 
‘combination therapy’ group. Our definition of ‘anticoagulant therapy’ for this study comprised 
anticoagulant therapy, with or without concomitant antiplatelet therapy. Our definition of ‘no 
anticoagulant therapy’ consisted patients either on ‘no therapy’ or ‘antiplatelet therapy’. We 
considered a patient’s index admission as their first admission within our data collection period 
with a diagnosis of AF that met the study’s inclusion criteria. Patients were followed for at least 
18 months from time of hospital discharge after their index admission or until the occurrence of a 
primary outcome, death or December 31, 2013, whichever occurred first. Our primary outcomes 
were: 1) major bleeding, including haemorrhagic stroke requiring hospitalisation, and 2) TE 
(ischaemic stroke and systemic embolism (SE), MI and TIA). Systemic embolism included an 
acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, 
retina or grafts). Major bleeding was defined as fatal or symptomatic bleeding in a critical area or 
organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, or 
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intramuscular with compartment syndrome, and/or bleeding causing a fall in haemoglobin level 
of 20g/L (1.24 mmol/L) or more, or leading to transfusion of at least two units of packed red 
blood cells.(222) 
 
We calculated the incidence rate (number of events per 100 person-years [PY]) by 
dividing the numbers of events by the PY of exposure. 
 
5.2.2 Statistical analysis 
Data were analysed using SPSS version 21 (Prentice Hall, USA). Continuous variables 
were expressed as mean ± standard deviation (SD). Categorical variables were expressed as 
frequencies and percentages. The rates of major bleeding and TE among different groups were 
compared using the Kaplan-Meier method and log-rank test. We calculated hazard ratios (HRs) 
and 95% confidence intervals (CIs) between the two groups using univariate Cox regression 
analysis. The a priori level of significance was < 0.05 for all analyses.  
 
We obtained ethics approval for the project from the Tasmanian Health and Medical 
Human Research Ethics Committee. 
 
5.3 Results 
5.3.1 Clinical characteristics 
The medical records of 1245 patients were reviewed, of whom 777 were included and 468 were 
excluded (episode of AF that reverted spontaneously or upon cardioversion: 228, developed AF 
as a short-term complication: 179, no documented AF [coding error]: 61). Forty-seven (6.1%) 
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index admissions were excluded due to death of the patient or unavailability of their records. 
Thus for this analysis we included 730 patients. Comparisons of the characteristics of the 
patients aged <75 and ≥75 years are shown in Table 5.1. It was observed that the elderly patients 
were significantly more likely to have cardiovascular and renal comorbidities and were at higher 
risk of bleeding and TE as per their risk assessment scores.  
 
 Table 5.1: Baseline characteristics of patients according to age  
Variable ≥75  (n=374) <75 (n=356) P value 
Age, years, mean (SD) 83.5 (±12.0)     65.2 (±12.6) <0.001* 
Gender, n (%)    
Male  167 (44.7) 250 (70.2) <0.001* 
Medical history, n (%)    
HTN 262 (70.1) 212 (59.6) 0.003* 
CHF 71 (67.2) 48 (13.5) 0.005* 
Diabetes 73 (19.5) 78 (21.9) 0.43 
Cerebrovascular disease 77 (20.6) 53 (14.9) 0.04* 
MI 61 (16.3) 37 (10.4) 0.02* 
Embolic events (DVT, pulmonary 
embolism etc.) 
22 (5.9) 18 (5.1) 0.62 
Peripheral vascular disease 16 (4.3) 18 (5.1) 0.62 
Bleeding history 20 (5.3) 3 (0.8%) <0.001* 
Renal disease 25 (6.7) 11 (3.1) 0.03* 
CHADS2, mean (±SD)  2.5 (±1.1) 1.3 (±1.1) <0.001* 
Low (score 0) 0 (0) 103 (28.9) <0.001* 
Intermediate (score 1) 67 (17.9) 126 (35.4)  
High (score 2-6) 307 (82.1) 127 (35.7)  
CHA2DS2-VASC, mean (±SD) 4.3 (±1.3) 2.4 (±1.5) <0.001* 
Low (score 0) 0 (0) 27 (7.6) <0.001* 
Intermediate (score 1) 0 (0) 85 (23.9)  
High (score 2-9) 374 (100%) 244 (68.5)  
HAS-BLED, mean (±SD) 2.0 (±0.8) 1.3 (±0.9) <0.001* 
Low (score 0) 1 (0.3) 63 (17.7) <0.001* 
Intermediate (score 1-2) 280 (74.9) 257 (72.2)  
High (≥3) 93 (24.9) 36 (10.1)  
CCI, mean (±SD) 5.8 (±1.8) 3.9 (±2.5) <0.001* 
AF duration, n (%)    
New onset 133 (35.6) 124 (34.8) 0.84 
Old 241 (64.4) 232 (65.2)  
Discharge eGFR, n (%)   <0.001* 
<30 39 (10.4) 29 (8.1)  
30-60 138 (36.9) 64 (18.0)  
>60 197 (52.7) 263 (73.9)  
Discharge antithrombotic therapy    
No therapy 45 (12.0) 30 (8.4) 0.11 
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Antiplatelet 138 (36.9) 115 (32.3) 0.19 
Anticoagulant 191 (51.1) 211 (59.3) 0.03* 
 AF, atrial fibrillation; CCI, Charlson comorbidity index; CHF, congestive heart failure; DVT, deep vein thrombosis; 
eGFR, estimated glomerular filtration rate (mL/min/1.73m2); HTN, hypertension; MI, myocardial infarction; SD, 
standard deviation. *= P<0.05 
 
5.3.2 Anticoagulant prescribing pattern at discharge  
We observed that elderly patients were significantly less likely to receive anticoagulant therapy 
(51.1% vs. 59.3%; P=0.03) compared to the younger group of patients during index admission 
discharge. There was also a significant difference in the rate of prescribing of anticoagulant 
therapy between the elderly and younger cohorts with a high risk of stroke (CHADS2 ≥2) - 
51.8% vs. 64.6% (P=0.02). In addition, 12.1% of patients aged ≥75 years with a CHADS2 score 
≥2 were not receiving any antithrombotic treatment (vs. 3.9% younger group; P=0.009) (Figure 
5.1). Elderly patients had significantly higher risk (HAS-BLED ≥3) of bleeding than the younger 
group (24.9% vs. 10.1%; P<0.001)). The mean HAS-BLED score of high-risk elderly patients 
was observed to be significantly higher than the younger group (2.1 vs. 1.8; P=0.002).  
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A 
 
B 
 
Figure 5.1: Antithrombotic prescribing pattern based on CHADS2 scores at discharge (A) ≥75 (B) <75 years 
 
5.3.3 Incidence rates of bleeding and TE 
During a mean of 2.2 years follow-up in the entire cohort (a total of 1600.8 PY), 29 major 
bleeding and 51 TE events were recorded. The annual incidences of major bleeding were 0.8% 
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and 3.1% per 100 PY with age <75 and ≥75 years, respectively. Similarly, the annual incidences 
of TE were 2.6% and 4.1% per 100 PY with age <75 and ≥75 years, respectively. The incidence 
rates of events during the follow-up for the two groups are shown in Table 5.2. Kaplan-Meier 
curves for the incidence of major bleeding and TE among each group are shown in Figure 5.2. 
Elderly patients had a higher risk of major bleeding (HR (Hazard ratio) 3.2, 95% CI 1.4-7.5, 
P=0.004) compared to the younger patients. We did not observe a significant difference in TE 
outcomes between the groups (HR 1.5, 95% CI 0.9-2.7, P=0.15).  
 
Elderly patients on anticoagulant therapy were at greater risk of major bleeding than 
those who were not (HR 3.0, 95% CI 1.1-8.3, P=0.02). There was no difference in the incidence 
rate of ICH between those treated and not treated with anticoagulant therapy (1.2 per 100 PY vs. 
0.4 per 100 PY; P=0.13). We however observed similar risk of TE (HR 0.9, 95% CI 0.4-1.8, 
P=0.69) between the elderly patients who were anticoagulated and those who were not. When we 
assessed the differences in baseline characteristics in elderly patients who were and were not 
prescribed anticoagulants (Table 5.3), more patients receiving anticoagulant therapy had CHF 
(24.5% vs. 13.2%; P=0.005) and a history of embolic disease (8.9% vs. 2.7%; P=0.01), while 
those not receiving anticoagulant therapy had a frequent history of bleeding (8.2% vs. 2.6%; 
P=0.02). We did not observe any differences in the mean CHADS2 (2.6 vs.2.4; P=0.16) or HAS-
BLED (1.9 vs. 2.1; P=0.11) scores between patients prescribed and not prescribed anticoagulant 
therapy. Incidence rates of events in the elderly patients based on anticoagulant therapy during 
the follow-up are shown in Table 5.4. The associations between anticoagulant prescribing and 
the outcomes among elderly patients are shown in Figure 5.3. 
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Table 5.2: Event rates (/100 person-years) of major bleeding and TE events (entire cohort based on age group) 
Events <75 
Total events 
(incidence 
rates) 
≥75 
Total events 
(incidence rates) 
<75 vs. ≥75 
HR (95% CI)
a
 
P value 
Major bleeding  
 
7 (0.8) 
 
22 (3.1) 
 
3.2 (1.4-7.5) 
 
0.004 
TE  22 (2.6) 29 (4.1) 1.5 (0.9-2.7) 0.15 
 
Ischaemic stroke/SE 
MI 
TIA 
13 (1.5) 
 
4 (0.5) 
5 (0.6) 
15 (2.1) 
 
12 (1.7) 
2 (0.3) 
1.4 (0.6-3.1) 
 
2.8 (0.9-8.9) 
0.5 (0.1-2.8) 
0.39 
 
0.06 
0.43 
MI: myocardial infarction; SE: systemic embolism; TIA: transient ischaemic attack; TE: thromboembolism. 
*others: epistaxis, retroperitoneal bleeding.  
a Hazard ratio presented with 95% confidence intervals.  
               
                                                             
                                       
     
Person-years follow-up for bleed (<75)=868.97, TE=849.30  
Person- years follow-up for bleed (≥75)=706.58, TE=702.78 
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Table 5.3: Baseline characteristics of elderly patients prescribed and not prescribed anticoagulants (n=374) 
Variable (-) anticoagulant  
(n=182) 
(+) 
anticoagulant 
(n=192) 
P value 
Age, years, mean (SD) 84.0 (±5.9)     82.9 (±4.9) 0.14 
Medical history, n (%)    
HTN 126 (69.2) 136 (70.8) 0.74 
CHF 24 (13.2) 47 (24.5) 0.005* 
Diabetes 29 (15.9) 44 (22.9) 0.09 
Cerebrovascular disease 39 (21.4) 38 (19.8) 0.70 
MI 31 (17) 30 (15.6) 0.71 
Embolic events (DVT, pulmonary 
embolism etc.) 
5 (2.7) 17 (8.9) 0.01* 
Peripheral vascular disease 7 (3.8) 9 (4.7) 0.69 
Bleeding history 15 (8.2) 5 (2.6) 0.02* 
Renal disease 12 (6.6) 13 (6.8) 0.95 
CHADS2, mean (±SD)  2.4 (±1.1) 2.6 (±1.2) 0.16 
CHA2DS2-VASC, mean (±SD) 4.2 (±1.3) 4.4 (±1.3) 0.10 
HAS-BLED, mean (±SD) 2.1 (±0.8) 1.9 (±0.8) 0.12 
CCI, mean (±SD) 5.7 (±1.8) 5.8 (±1.9) 0.65 
Discharge antithrombotic therapy   <0.001* 
 
No therapy 47 (25.8) 0 (0)  
Antiplatelet 135 (74.2) 0 (0)  
Combination 0 (0) 62 (32.2)  
Anticoagulant 0 (0) 130 (67.7)  
AF, atrial fibrillation; CCI, Charlson comorbidity index; CHF, congestive heart failure; DVT, deep vein thrombosis; 
eGFR, estimated glomerular filtration rate (mL/min/1.73m
2
); HTN, hypertension; MI, myocardial infarction; SD, 
standard deviation. 
*=P<0.05 
 
Table 5.4: Major bleeding and TE rates (/100 person-years) according to anticoagulant therapy on discharge 
(elderly cohort: 374) 
Events (-) anticoagulant 
(182) 
(+) anticoagulant 
(192) 
HR (95% CI)a P 
value  
Major bleeding 5 (0.9) 17 (2.9) 3.0 (1.1-8.3) 
 
0.02 
TE 15 (4.7) 14 (3.7) 0.9 (0.4-1.8) 
 
0.69 
Ischaemic stroke/SE 
 
7 (2.1) 8 (2.1) 1 (0.4-2.8) 
 
1.0 
MI 7 (2.1) 5 (1.3) 0.7 (0.2-2.3) 
 
0.57 
TIA 1 (0.3) 1 (0.3) 0.8 (0.1-13.1) 
 
0.89 
MI: myocardial infarction; SE: systemic embolism; TIA: transient ischaemic attack; TE: thromboembolism. 
*others: epistaxis, retroperitoneal bleeding.  
a Hazard ratio presented with 95% confidence intervals.  
Person-years follow-up (- anticoagulant): bleed=559.92, TE=322.03  
Person- years follow-up (+ anticoagulant): bleed=580.09, TE=380.76  
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A 
 
HR (CI)=3.2 (1.4-7.5), Log rank; P=0.004 
B 
 
HR (CI)=1.5 (0.9-2.7), Log rank; P=0.15 
 
Figure 5.2: Cumulative hazard rates of (A) Major bleeding (B) TE, in patients <75 (=0) vs. ≥75 (=1) years 
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A 
 
HR (CI)=3.0 (1.1-8.3), Log rank; P=0.02 
B 
 
HR (CI)=0.9 (0.4-1.8), Log rank; P=0.69 
 
Figure  5.3: Cumulative hazard rates of (A) Major bleeding (B) TE, in patients ≥75 with (=1) or without (=0) 
anticoagulant therapy 
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5.4 Discussion 
The Tasmanian Atrial Fibrillation (TAF) study is an observational study designed to 
comprehensively evaluate the management and outcomes of patients with AF. The dataset is the 
largest and most recent of its kind in Australia. In this paper, we compared the patient 
characteristics, antithrombotic prescribing patterns, and rates of major bleeding or TE outcomes 
between older and younger patients diagnosed with AF admitted to one of the major hospitals in 
Tasmania, Australia. We observed significant difference in the rate of prescribing of 
anticoagulant therapy between the elderly and younger cohorts. Being aged ≥75 years was 
however associated with a higher risk of major bleeding events and this was significantly 
associated with the use of anticoagulant therapy in this group of patients.  
 
Despite all the proven benefits, early discontinuation and underuse of anticoagulant 
therapy in real-world practice have often been reported due to reasons like history of anaemia, 
history of hospitalisation/emergency room visits, elderly age, comorbidities, risk of falls and 
previous bleeding.(103, 133, 203, 206) Studies have identified underuse of anticoagulant therapy 
among elderly people due to the fear of bleeding.(197, 215) In contrast, benefits of anticoagulant 
therapy have been proven in clinical trials conducted among elderly patients.(204, 216) and 
hence their use should not be discounted among elderly high-risk groups. Risk of stroke has been 
shown to increase without anticoagulation therapy in patients ≥75 years.(73) In our study, only 
half of the high-risk elderly patients were receiving anticoagulant therapy. The underuse of 
anticoagulant therapy is likely to have been influenced by the higher bleeding risk in this cohort 
compared to the younger group. Since bleeding has been proven to be one of the most feared 
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complications of anticoagulant use among treating physicians, (205) this might have influenced 
physicians’ prescribing decisions among elderly patients in our study despite their stroke risk.  
 
We observed that elderly patients were at higher risk of major bleeding outcomes 
compared to younger ones. Older patients have organ function decline leading to increased risk 
of both bleeding and ischaemic events.(236) Moreover, the higher vulnerability of elderly 
patients may be related to drug-drug interactions due to polypharmacy further enhancing the risk 
of adverse effects associated with the use of antithrombotic agents.(239) Our elderly patient 
group was at higher risk of major bleeding as depicted by their mean HAS-BLED score, and 
higher rates of pre-existing renal impairment and previous bleeding disease history compared to 
the younger group. This might have predisposed them towards more major bleeding. When we 
grouped elderly patients based on whether or not they were prescribed an anticoagulant, those on 
anticoagulant therapy were at significantly higher risk of major bleeding compared to those not 
on anticoagulant therapy. The incidence rate of ICH was not higher among those on 
anticoagulant therapy. The mean HAS-BLED score between these two groups was also 
comparable but those on anticoagulant therapy had higher prevalence of CHF and embolic 
disease. Other age-related physiological changes and factors or suboptimal INR control may 
have been associated with this outcome and these need to be explored in similar studies in a 
larger population. We observed the incidence rate of major bleeding to be 2.9 per 100 person-
years in the elderly patient group treated with anticoagulant therapy. Studies have reported major 
bleeding rates ranging from 1.1-13.1% per year with the use of anticoagulant therapy in elderly 
patients with AF.(236, 240-244) The rate of major bleeding among our elderly patient is thus 
comparable to the rates reported in other real-world studies.  
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Although older patients are known to have an increased risk of ischaemic events, (236) 
we did not observe significant difference in the incidences of TE overall and ischaemic stroke/SE 
outcomes in them compared to younger ones. Surprisingly, there was also a lack of difference in 
the incidence of stroke/SE between elderly patients treated and not treated with anticoagulants. 
The lack of difference in the rates between those treated and not treated could have been 
influenced by the small sample size of the study and consequently low number of events 
reported. Our rate of ischaemic stroke/SE was 2.1 per 100 person-years among elderly patient 
treated with anticoagulant therapy. Higher rates of ischaemic stroke/SE have been reported (7.1-
8 per 100 person-years) in similar elderly populations in some real-world studies.(240, 245) One 
of these studies paradoxically reported that the incidence of stroke/SE was higher in extreme 
elderly patients receiving OAC than in those not receiving therapy.(245) Suboptimal INR control 
leading to higher incidence of stroke in anticoagulant-treated patients was one of the reasons 
proposed for such paradoxical finding in this study. In our study, this finding may be explained 
by the differences in baseline characteristics between groups, specifically the significantly higher 
proportions of elderly patients with a history of a TE event who were prescribed anticoagulants. 
Nonetheless, larger studies are needed to confirm the benefits and risks of anticoagulant therapy 
in reducing stroke/SE in elderly patients. 
 
5.5 Conclusion 
In this real-world longer-term follow-up study, underuse of anticoagulant therapy among elderly 
compared to younger patients with AF was evident. Elderly patients with AF were at higher risk 
of major bleeding but similar risk of TE compared to younger patients in this cohort. Elderly 
patients who were prescribed anticoagulants had a significantly higher risk of major bleeding 
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that those who were not, but interestingly, had a similar risk of TE events. This finding requires 
further investigation as it has important implications for management, and may have been due to 
the confounding effects of antiplatelet agents being used alone or in combination with 
anticoagulants, differences in the characteristics of elderly patients prescribed and not prescribed 
anticoagulants, poor control of anticoagulant therapy or other unknown underlying patient 
characteristics in elderly patients. 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
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Chapter 6: Concluding Discussion 
 
6.1 Discussion 
The Commonwealth Review of Anticoagulation Therapies in AF in Australia (2012) identified 
several issues to be addressed in regards to the proper management of patients with AF.(53) It 
also argued for the need for local data on which to base recommendations regarding the 
treatment of AF. As a starting point to addressing these recommendations, we initiated the TAF 
study, which is an observational study designed to comprehensively evaluate the management 
and outcomes of patients with AF. The studies included in this thesis explore the patient 
characteristics, antithrombotic prescribing patterns, factors associated with anticoagulant 
prescribing, rates of and risk factors of bleeding and TE-related hospitalisation for the patients 
enrolled in the TAF study between 1
st
 January 2011 and 30
th
 June 2012. These studies provide 
crucial local data to aid in the proper selection of antithrombotic drugs for individual patients to 
minimise the incidences of bleeding and TE in Australian patients. These findings will form the 
basis for ongoing research to monitor the management of AF in Tasmania in the future. 
 
In chapter 2, the characteristics of patients with AF admitted to the three major 
Tasmanian hospitals and the appropriateness of antithrombotic prescribing according to 
guideline recommendations were presented. Firstly, this study showed that the patients in our 
study are comparable to the patient cohorts studied in recent AF-based registries, meaning that 
the Australian population is broadly comparable to other countries. Additionally, comparability 
of patient characteristics in terms of mean age and stroke risk with recent trials allows for the 
transferability of the benefits obtained from those trials to the Australian population. Secondly, 
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we also confirmed the suboptimal use of antithrombotic therapy in this cohort. All contemporary 
guidelines recommend prophylaxis with antithrombotic agents in people with AF and at least one 
other risk factor for stroke (7, 16) however discordance between AF guideline recommendations 
and anticoagulant prescribing patterns has been reported in various international studies.(103, 
202) Our study also highlighted the underuse of anticoagulants according to guidelines. We 
observed underutilisation of anticoagulant therapy despite the high-risk of stroke in our 
population. This underutilisation could have been influenced by several factors such as HAS-
BLED score exceeding the CHADS2 score among those without any CIs, the majority of patients 
being elderly with multiple comorbidities in this cohort, belief that antiplatelet therapy alone is 
sufficient for stroke prophylaxis and lack of awareness of guideline recommendations.(194) 
Thirdly, we observed relatively high rate of prescribing of combination anticoagulant/antiplatelet 
therapy among patients newly initiated on therapy and in patients with existing AF at discharge. 
This issue warrants further investigation in order to identify the reasons for increase in 
combination prescribing as combination therapy is associated with a significantly higher risk of 
bleeding.(16) Overall, this study highlighted the need to identify the factors associated with 
anticoagulant prescribing among patients with AF and to compare the changes pattern of 
anticoagulant prescribing over the years in Tasmania.   
 
In chapter 3, key factors associated with anticoagulant prescribing among patients with 
NVAF were presented. The results of a comparison between the anticoagulant utilisation patterns 
with earlier data in the same population were also reported. In this study we identified various 
factors that influence prescribers to prescribe anticoagulant therapy as thromboprophylaxis at 
discharge. Younger age, CHADS2=1 (relative to 0), CHF and embolic disease history were 
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identified to be the significant predictors of anticoagulant prescribing in our population. CHF has 
been previously associated with a higher rate of oral anticoagulation use, (212) and previous TE 
is now clearly acknowledged as a risk factor for stroke through its inclusion in the CHA2DS2-
VASc scoring system.(20) Benefits of anticoagulant therapy have been proven in clinical trials 
conducted among elderly patients (204, 216) and hence their use should not be overlooked 
among elderly high-risk groups. Our findings thus potentially suggest that the prescribers during 
this study period were less aware of the contemporary guideline recommendations of 
anticoagulant therapy among those with a CHADS2 score ≥2.(7, 16) Fear of bleeding-related 
complications may have influenced their decision regarding the use of thromboprophylaxis in 
patient with CHADS2 ≥2 and older age. Secondly, we observed improvements in anticoagulant 
prescribing among high-risk AF patients in Tasmania over the past 15 years and this most likely 
reflects increased focus on the importance of effective thromboprophylaxis as recommended in 
international guidelines, as well as the results of previous local intervention studies.(7, 16, 208) 
Future interventional studies comprising guideline dissemination strategies targeting the 
prescribers in multiple states of Australia can prove to be helpful to improve guideline adherence 
among the physicians. After evaluating the baseline details, we felt the need for examining the 
outcomes in terms of major bleeding and TE and the associated risk factors for such outcomes in 
this cohort. 
 
In chapter 4, we have presented the rates of readmissions due to major bleeding or TE 
during short and longer-term follow-up periods among patients with newly diagnosed AF at the 
major hospital in Tasmania, Australia. We also identified the risk factors for readmission due to 
major bleeding or TE during longer-term follow-up. In this study, we observed a higher 
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incidence of major bleeding and TE during 3-month than longer-term follow up in other real 
world studies.(220, 221, 223). In comparing our rates to ‘real-world’ study data, the longer-term 
rate per 100 PY of stroke/SE events was comparable but the rate per 100 PY of major bleeding 
events was lower.(226) Our higher 3-month rates warrant the need for further investigation that 
involves the monitoring of anticoagulation control after initiation of warfarin. We also identified 
that history of MI was the only predictor for TE. A history of PVD and reduced eGFR were 
predictors of major bleeding-related readmissions. The risk of stroke and/or the composite TE 
endpoint (stroke, TIA, or SE) has been found to increase independently in the presence of 
vascular disease in patients with AF, (34) which is also reflected in the recent inclusion of MI as 
a risk factor for stroke in CHA2DS2-VASc. Our results suggest a need for a particular focus on 
the optimal prescribing in this group of patients so as to reduce the risk of stroke. Our findings 
suggest that these risk factors should be considered as potential ‘red flags’ when managing 
patients with AF, and patients with these conditions should receive special attention when 
managing concomitant AF. Since increasing age was identified as one of the negative predictors 
of anticoagulant prescribing in our population, we conducted a study to compare the patient 
characteristics, antithrombotic prescribing patterns, and rates of bleeding and TE outcomes 
between older and younger patients diagnosed with AF in our cohort. 
 
In chapter 5, the results of examining and comparing the patient characteristics, 
antithrombotic prescribing patterns, and rates of bleeding or TE outcomes during longer-term 
follow-up between older and younger patients diagnosed with AF in Tasmania have been 
presented. In this study we observed underuse of anticoagulant therapy among high-risk elderly 
patients compared to the younger group despite its proven benefits.(204, 216) Bleeding risk has 
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been proven as one of the most feared complications of anticoagulant use among treating 
physicians. (205) This might have influenced physicians’ prescribing decisions among elderly 
patients in our study despite their stroke risk. In this cohort, elderly patients had a higher mean 
HAS-BLED score, and higher rates of renal impairment and bleeding disease history. These 
factors might have predisposed this group to a higher rate of major bleeding outcomes compared 
to that in the younger patients. Our rate of bleeding with anticoagulant use among elderly 
patients was comparable to the rates (1.1-13.1% per year) reported in other real world 
studies.(236, 240-244) Our rate of ischaemic stroke/SE among the elderly patients treated with 
anticoagulant therapy was however lower (2.1 vs. 7.1-8 per 100 PY) than in some of the real-
world studies.(240, 245) As mentioned above, further investigation that involves the monitoring 
of anticoagulation control after initiation of warfarin may explain our results more meaningfully.    
 
In summary, our results suggest that though there has been some improvement in the use 
of anticoagulant therapy among high-risk patients with AF over the past 15 years in Tasmania, 
further developments are required so as to improve adherence to stroke risk stratification 
schemes for antithrombotic prophylaxis in AF and to potentially reduce stroke outcomes in our 
population. The observed issues of over-use of anticoagulant therapy in low risk patients, under-
use in high risk patients and inappropriate use of combination therapy in patients with AF need 
to be addressed in order to minimise the unwanted risk of stroke and bleeding related 
complications in patients with AF.    
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6.2 Limitations 
The results of our study are subject to some limitations of observational research such as the 
collection of non-randomized data and recording of incomplete and missing information. Recent 
hospitalisation for surgery may have constituted a reasonable indication for temporary cessation 
of anticoagulation, which may have influenced the findings regarding suboptimal 
anticoagulation. We only included patients with AF who experienced a hospitalisation meaning 
that they were potentially already at higher risk than ‘average’ Tasmanian patients with AF. This 
could limit the generalisability of our results to the broader Australian population. The rates of 
bleeding and TE in our study might have been influenced by the relatively small sample size of 
our study as well as due to the inclusion of patients with AF who experienced a hospitalisation. 
Lack of data regarding INR and TTR for those patients taking warfarin therapy led to difficulty 
in interpreting our findings related to our outcomes and predictors. Lastly, we had to assume the 
continuation of discharge antithrombotic therapy for patients not readmitted due to bleeding or 
TE. This could potentially limit the generalisability of our results in real-world practice, where 
changes in antithrombotic therapy could have been made during the entire follow-up period, 
even for those readmitted due to reasons other than bleeding or TE.  
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6.3 Future directions 
While our study provides critical local data on the existing AF management pattern in an 
Australian sub-population prior to the PBS listing of DOACs, further investigations are required 
before implementing our findings to the clinical practice. The following recommendations are 
made as a result of this body of work: 
 
1. Prospective studies enrolling prescribers in multiple states of Australia are required to 
substantiate our underutilisation findings and to better understand the existing barriers to 
guideline recommended antithrombotic prescribing. Interventional studies should then be 
designed to better support prescribers to assist in the identification and quantification of 
patient risk according to accepted international guidelines to optimise 
thromboprophylaxis and reduce the risk of thromboembolic and bleeding complications 
in this vulnerable patient group. We recommend that interventional studies should mainly 
address the issues of 1) under-use of anticoagulant therapy in high risk patients, 2) over-
use of anticoagulant therapy in low risk patients, and 3) potentially inappropriate use of 
combination therapy in patients with AF. Such studies would be helpful in terms of 
exploring the reasons behind antithrombotic underutilisation. Such studies can even act as 
a good platform for disseminating information regarding recent AF management 
guidelines to the prescribers.  
 
2. Interventional studies should be designed to optimise antithrombotic therapy prescribing 
in patients with history of PVD, MI and renal impairment so as to reduce bleeding and 
TE-related adverse events in patients with AF and these comorbidities.  
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3. Larger studies among extreme elderly (≥75 years) patients with AF, in multiple hospitals, 
are required so as to optimise stroke prophylaxis and to reduce bleeding associated 
adverse outcomes in this high-risk group. 
 
4. We recommend the ongoing monitoring of prescribing practices in the light of increasing 
use of DOACs in Australia. Future analysis of TAF study data will help to explore the 
current trend of DOAC uptake after their PBS listing, and to identify their safety and 
efficacy profiles in the Australian population.  
 
5. Lastly, we recommend the formulation of robust national AF management guidelines so 
as to better support prescribers to assist with guideline concordance. Formulation of 
national guidelines and their effective dissemination to physicians can improve the 
proportion of Australian patients receiving appropriate thromboprophylaxis for stroke 
prevention in AF. 
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8.2 Appendix B  
Data collection sheet 
FIRST ADMISSION  
DEMOGRAPHICS AND MEDICAL HISTORY DETAILS 
Patient ID:       Date of admission: 
 
Gender:       M     F  DOB:    Date of discharge: 
 
Weight:  Admitted unit:     Post Code: 
 
Final Diagnosis: 
 
Lives:   At home with family/carer      At home alone    Institutionalised 
 
Smoking:  Current smoker  Ex- Smoker    Never smoked    Unsure 
 
Alcohol:  Yes   No 
If yes,  one or fewer alcoholic drinks per week  2-7 alcoholic drinks per week   Unsure 
  8-14 alcoholic drinks per week  15 or more alcoholic drinks per week  
  
Co-morbid conditions 
MI .........................................................  Yes .......  No ..... (history of medically documented MI) 
CHF .......................................................  Yes .......  No ..... (Documented history of CHF) 
PVD .......................................................  Yes .......  No ..... (intermittent claudication, periph.arterial bypass for 
insufficiency, gangrene, actual arterial insufficiency, 
untreated) 
CVD .......................................................  Yes .......  No ..... (HX of TIA, or CVA with no or minor sequelae) 
Dementia ..............................................  Yes .......  No ..... (Chronic progressive syndrome due to disease of 
brain in which there is disturbance of multiple 
higher cortical function including memory, thinking 
,orientation, comprehension, calculation, learning 
capability, language, and judgement) 
Chronic Respiratory Disease ..................  Yes .......  No ..... (symptomatic dyspnea due to chronic respiratory 
conditions (asthma, COPD, bronchitis) 
Ulcer Disease.........................................  Yes .......  No ..... (PUD) 
Connective tissue disease ......................  Yes .......  No ..... (SLE,RA,Scleroderma, sjogren’s disease) 
AIDS ......................................................  Yes .......  No ..... (most advanced stages of HIV infection defined by  
the occurrence of any of more than 20 
opportunistic infections or HIV-related cancers) 
Diabetes ................................................  Yes .......  No ..... (diabetes with medication) 
Diabetes with end organ damage ..........  Yes .......  No ..... (retinopathy,neuropathy,nephropathy) 
Moderate or severe renal disease ..........  Yes .......  No ..... (Cr>265 micromol/l, dialysis, transplantation, 
uraemic syndrome) (At discharge) 
Hemiplegia (or paraplegia)  ....................  Yes .......  No ..... (Hemiplegia or paraplegia) 
Any solid tumor  ....................................  Yes .......  No ..... (any malignancy incl. lymphoma/leukaemia for 
updated criteria) 
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Leukaemia .............................................  Yes .......  No ..... (CML, CLL, AML,ALL,*PV) 
Lymphoma ............................................  Yes .......  No ..... (NHL,Hodgkin’s, Waldenstrom, multiple myeloma) 
Moderate or severe liver disease ...........  Yes .......  No ..... (cirrhosis with portal +/- variceal bleeding) (At 
discharge) 
Mild liver disease...................................  Yes .......  No ..... (cirrhosis without portal HT, chronic hepatitis) 
Metastatic solid tumor ..........................  Yes .......  No 
Valvular heart disease ...........................  Yes .......  No .....  
Other Embolic events ............................  Yes .......  No ..... (pulmonary embolism, DVT) 
Hypertension.........................................  Yes .......  No .....  Systolic BP (Discharge):   
    Diastolic BP:  
 
Uncontrolled hypertension (SBP>160mmHg) (Discharge) .........   Yes  No  
IHD (angina), other vascular disease (aortic plaque)     Yes  No  
 
Medications on Admission 
 DRUG DOSE FREQUENCY 
1  
 
  
2  
 
  
3  
 
  
4  
 
  
5  
 
  
6  
 
  
7  
 
  
8    
 
  
9  
 
  
10  
 
  
11  
 
  
12  
 
  
13  
 
  
14  
   
  
Notes: 
 
 
 
 
Allergies to antithrombotics?    No  Yes - Details:  
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Duration of AF in a patient:  First detected    Other: 
Rhythm recorded:    Paroxysmal AF   Persistent AF   Permanent 
AF   
  
INR on admission (only if taking warfarin): 
 
Risk factors for bleed (HAS BLED)  
 Labile INR (<60% time in therapeutic range/ unstable/high INRs)          
 Prior major bleeding or predisposition to bleeding (Haemophilia etc.) 
 
CI to antithrombotic therapy:    Yes   No  
Psychosis  H/O asthma induced by NSAIDs   Pregnancy  
 
IN-PATIENT ADMISSION DETAILS 
Reason for admission  
 Related to AF                                                Thromboembolic event (Ischaemic stroke, TIA, PE or other)  
 Bleeding (ICH or other)                              Unrelated to AF-related cardiovascular admission   None of the 
above 
 
If due to bleeding 
 Bleeding secondary to INR> 10    
  Bleeding due to DDIs (e.g. warfarin with metronidazole, cephalexin, tamoxifen 
 GI bleeding due to excess alcohol intake (e.g. 48 stubbies in 2 days in patient taking aspirin) 
 Fatal                                  Major                                     Minor  See Definition 
 
Brain imaging (for confirmation)   Head CT                              MRI 
 
Anatomic site of haemorrhage 
 Intracranial            Upper gastrointestinal      Lower gastrointestinal    Intraspinal   Pericardial    
 Retroperitoneal    Other 
 
Bleeding due to antithrombotic was managed with: 
 Drug stopped Fluid replacement Vitamin K1 Fresh frozen plasma 
 Tranexamic acid  Prothrombinex-VF  Oral charcoall Factor VIIa  
 Hemodialysis Charcoal Haemofiltration  Inotropic agents  
 
Transfusion (units or millilitres)  
 Whole blood              packed red blood cells         platelets         other blood products    
 
If due to thromboembolism: Thromboembolism was managed with  
 Anticoagulant therapy (LMWH, warfarin) 
 Thrombolytic therapy (streptokinase, tissue plasminogen activator, urokinase) 
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Details of Medication administered to manage bleeding or stroke 
Drug Doses Duration 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
Notes:  
 
Details of Procedures used to manage bleeding or stroke 
Procedures Rationale 
  
  
  
  
  
  
Notes:  
 
Antithrombotic therapy (during hospital stay) 
 DRUGS DOSE FREQUENCY 
1  
 
  
2  
 
  
3  
 
  
4  
 
  
5  
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INR values throughout admission 
Day INR 
 
Warfarin 
(Doses in mg) 
Notes Day INR 
 
Warfarin (Doses 
in mg) 
Notes 
 
 
    
 
   
 
 
    
 
   
 
 
    
 
   
 
 
    
 
   
 
 
    
 
   
 
Inpatient care  
 Investigations  
 
 Cardioversion (electrical or pharmacologic cardioversion) 
 
 Surgery (surgical procedures) 
 
Adverse drug reaction observed (if any, defined)  
Details: 
 
Severity    Mild   Moderate  Severe  Fatal 
Causality    Doubtful  Possible    Probable Definite 
Preventable  Yes       NO 
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DISCHARGE DETAILS 
 
Laboratory reports on discharge:  
Test Values Notes 
Serum creatinine (60-115 µmol/L)   
GFR (>90 Ml/min/1.73m2)   
Serum albumin (32-45 g/L)   
ALP (25-100 U/L)   
ALT (<35 U/L)   
GGT (F<30, M<50 U/L)   
Total bilirubin: (<20 µmol/L)   
Hb (130-175 g/L)   
Platelet count (160-420/nL)   
PTT (10-14 seconds)   
APTT (25-45 seconds)   
TT (14-16 seconds)   
Systolic BP (120 mmHg)   
Diastolic BP (80 mmHg)   
   
 
Patient outcome 
 Complete/near-complete recovery (able to return to pre-admission level of function) 
 Mild to moderate deficit (deficits present, but patient can perform activities of daily living, such as dressing and       
feeding, with or without assistance) 
 Severe deficit (required assistance to complete activities of daily living) 
 Death 
 
Reasons for not initiating or discontinuation antithrombotic:  
 Poor adherence                                    Falls                                   Ineffective 
 Patient refusal                                      Physicians decision         ADRs 
 
Antithrombotic therapy:   
 Newly initiated                                                Changed       
 Continued                                                         Stopped 
 Recommendation for commencement in community  No therapy  N/A 
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Details: 
Discharge medications:  
 DRUG DOSE FREQUENCY 
1  
 
  
2  
 
  
3  
 
  
4  
 
  
5  
 
  
6  
 
  
7  
 
  
8    
 
  
9  
 
  
10  
 
  
11  
 
  
12  
 
  
13  
 
  
14  
   
  
15  
 
  
16  
 
  
17  
 
  
Notes: 
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RE-ADMISSION  
DEMOGRAPHICS AND MEDICAL HISTORY DETAILS 
Patient ID:       Date of admission: 
 
Gender:       M     F DOB:    Date of discharge: 
 
Weight:  Admitted unit:     Post Code: 
 
Final Diagnosis: 
 
Lives:   At home with family/carer      At home alone    Institutionalised 
 
Smoking:  Current smoker  Ex- Smoker    Never smoked    Unsure 
 
Alcohol:  Yes   No 
If yes,  one or fewer alcoholic drinks per week  2-7 alcoholic drinks per week   Unsure 
  8-14 alcoholic drinks per week  15 or more alcoholic drinks per week  
 
Co-morbid conditions 
MI .........................................................  Yes .......  No ..... (history of medically documented MI) 
CHF .......................................................  Yes .......  No ..... (Documented history of CHF) 
PVD .......................................................  Yes .......  No ..... (intermittent claudication, periph.arterial bypass for 
insufficiency, gangrene, actual arterial insufficiency, 
untreated) 
CVD .......................................................  Yes .......  No ..... (HX of TIA, or CVA with no or minor sequelae) 
Dementia ..............................................  Yes .......  No ..... (Chronic progressive syndrome due to disease of 
brain in which there is disturbance of multiple 
higher cortical function including memory, thinking 
,orientation, comprehension, calculation, learning 
capability, language, and judgement) 
Chronic Respiratory Disease ..................  Yes .......  No ..... (symptomatic dyspnea due to chronic respiratory 
conditions (asthma, COPD, bronchitis) 
Ulcer Disease.........................................  Yes .......  No ..... (PUD) 
Connective tissue disease ......................  Yes .......  No ..... (SLE,RA,Scleroderma, sjogren’s disease) 
AIDS ......................................................  Yes .......  No ..... (most advanced stages of HIV infection defined by  
the occurrence of any of more than 20 
opportunistic infections or HIV-related cancers) 
Diabetes ................................................  Yes .......  No ..... (diabetes with medication) 
Diabetes with end organ damage ..........  Yes .......  No ..... (retinopathy,neuropathy,nephropathy) 
Moderate or severe renal disease ..........  Yes .......  No ..... (Cr>265 micromol/l, dialysis, transplantation, 
uraemic syndrome) (At discharge) 
Hemiplegia (or paraplegia)  ....................  Yes .......  No ..... (Hemiplegia or paraplegia) 
Any tumor  ............................................  Yes .......  No ..... (any malignancy incl. lymphoma/leukaemia for 
updated criteria) 
Leukaemia .............................................  Yes .......  No ..... (CML, CLL, AML,ALL,*PV) 
Lymphoma ............................................  Yes .......  No ..... (NHL,Hodgkin’s, Waldenstrom, multiple myeloma) 
Moderate or severe liver disease ...........  Yes .......  No ..... (cirrhosis with portal +/- variceal bleeding) (At 
discharge) 
Mild liver disease...................................  Yes .......  No ..... (cirrhosis without portal HT, chronic hepatitis) 
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Metastatic solid tumor ..........................  Yes .......  No 
Valvular heart disease ...........................  Yes .......  No .....  
Other Embolic events ............................  Yes .......  No ..... (pulmonary embolism, DVT) 
Hypertension.........................................  Yes .......  No .....  Systolic BP (Discharge):   
    Diastolic BP:  
 
Uncontrolled hypertension (SBP>160mmHg) (Discharge) .........   Yes  No  
IHD (angina), other vascular disease (aortic plaque)     Yes  No  
 
Previous medication history  
 DRUG DOSE Frequency 
1  
 
  
2  
 
  
3  
 
  
4  
 
  
5  
 
  
6  
 
  
7  
 
  
8  
 
  
9  
 
  
10  
 
  
11  
 
  
12  
 
  
13  
 
  
14  
 
  
15  
 
  
16  
 
  
17  
 
  
18  
 
  
19  
 
  
Notes: 
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Allergies to antithrombotics?   No  Yes - Details:  
 
Duration of AF in a patient:  First detected    Other: 
Rhythm recorded:    Paroxysmal AF   Persistent AF   Permanent 
AF   
  
INR on admission (only if taking warfarin):  
Risk factors for bleed (HAS BLED)  
 Labile INR (<60% time in therapeutic range/ unstable/high INRs)          
 Prior major bleeding or predisposition to bleeding (Haemophilia etc.) 
 
CI to antithrombotic therapy:    Yes   No  
Psychosis  H/O asthma induced by NSAIDs   Pregnancy  
 Prior major bleeding or predisposition to bleeding (Haemophilia etc.) 
 
IN-PATIENT ADMISSION DETAILS 
Reason for re-admission  
 Related to AF                                                Thromboembolic event (Ischaemic stroke, TIA, PE or other)  
 Bleeding (ICH or other)                               Unrelated to AF (e.g. MI)   
 
If due to bleeding 
 Bleeding secondary to INR> 10    
  Bleeding due to DDIs (e.g. warfarin with metronidazole, cephalexin, tamoxifen 
 GI bleeding due to excess alcohol intake (e.g. 48 stubbies in 2 days in patient taking aspirin) 
 Fatal                                  Major                                     Minor  See Definition 
 
Brain imaging (for confirmation)   Head CT                              MRI 
 
Anatomic site of haemorrhage 
 Intracranial            Upper gastrointestinal      Lower gastrointestinal    Intraspinal   Pericardial    
 Retroperitoneal     Other 
 
Bleeding due to antithrombotic was managed with: 
 Drug stopped Fluid replacement Vitamin K1 Fresh frozen plasma 
 Tranexamic acid  Prothrombinex-VF  Oral charcoall Factor VIIa  
 Hemodialysis Charcoal Haemofiltration  Inotropic agents  
 
Transfusion (units or millilitres)  
 Whole blood              packed red blood cells         platelets         other blood products    
 
If due to thromboembolism: Thromboembolism was managed with  
 Anticoagulant therapy (LMWH, warfarin) 
 Thrombolytic therapy (streptokinase, tissue plasminogen activator, urokinase) 
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Details of Medication administered to manage bleeding or stroke 
Drug Doses Duration 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
Notes:  
 
Details of Procedures used to manage bleeding or stroke 
Procedures Rationale 
  
  
  
  
  
  
Notes:  
 
Antithrombotic therapy (during hospital stay) 
 DRUGS DOSE FREQUENCY 
1  
 
  
2  
 
  
3  
 
  
4  
 
  
5  
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INR values throughout admission 
Day INR 
 
Warfarin 
(Doses in mg) 
Notes Day INR 
 
Warfarin (Doses 
in mg) 
Notes 
 
 
    
 
   
 
 
    
 
   
 
 
    
 
   
 
 
    
 
   
 
 
    
 
   
 
Inpatient care  
 Investigations  
 
 Cardio version (electrical or pharmacologic cardioversion) 
 
 Surgery (surgical procedures) 
 
 
Adverse drug reaction observed (if any, defined)  
Details: 
 
Severity    Mild   Moderate  Severe  Fatal 
Causality    Doubtful  Possible    Probable Definite 
Preventable  Yes                      NO 
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DISCHARGE DETAILS 
 
Laboratory reports on discharge:  
Test Values Notes 
Serum creatinine (60-115 µmol/L)   
GFR (>90 Ml/min/1.73m2)   
Serum albumin (32-45 g/L)   
ALP (25-100 U/L)   
ALT (<35 U/L)   
GGT (F<30, M<50 U/L)   
Total bilirubin: (<20 µmol/L)   
Hb (130-175 g/L)   
Platelet count (160-420/nL)   
PTT (10-14 seconds)   
APTT (25-45 seconds)   
TT (14-16 seconds)   
Systolic BP (120 mmHg)   
Diastolic BP (80 mmHg)   
   
 
Patient outcome 
 Complete/near-complete recovery (able to return to pre-admission level of function) 
 Mild to moderate deficit (deficits present, but patient can perform activities of daily living, such as dressing and       
feeding, with or without assistance) 
 Severe deficit (required assistance to complete activities of daily living) 
 Death 
 
Reasons for not initiating or discontinuation antithrombotic:  
 Poor adherence                                    Falls                                   Ineffective 
 Patient refusal                                      Physicians decision         ADRs 
 
Antithrombotic therapy:   
 Newly initiated                                                Changed       
 Continued                                                        Stopped 
 Recommendation for commencement in community  No therapy  N/A 
 
Details: 
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Discharge medications:  
 DRUG DOSE FREQUENCY 
1  
 
  
2  
 
  
3  
 
  
4  
 
  
5  
 
  
6  
 
  
7  
 
  
8    
 
  
9  
 
  
10  
 
  
11  
 
  
12  
 
  
13  
 
  
14  
   
  
15  
 
  
16  
 
  
17  
 
  
18  
 
  
19  
 
  
20  
 
  
21  
 
  
Notes: 
 
 
 
